background
aim
spread
gastrointestin
diseas
grow
world
although
effect
therapeut
approach
found
palliat
rather
cure
frequent
due
partial
knowledg
aethiolog
pathogenesi
review
analyz
main
clinic
studi
aim
state
art
updat
use
probiot
formul
daili
practic
method
review
includ
signific
clinic
trial
involv
use
probiot
formul
treatment
sever
patholog
result
dysbiosi
observ
irrit
bowel
syndrom
patient
probiot
may
exert
benefici
effect
crohn
diseas
affect
patient
shown
gut
microbiota
antigen
alter
wall
permeabl
moreov
probiot
formul
seem
enhanc
therapi
helycobact
pylori
reduc
pathogen
potenti
intestin
ecolog
imbal
also
link
cancer
induct
allergi
skin
urogenit
diseas
addit
probiot
administr
seem
particularli
use
eas
postop
complic
conclus
futur
clinic
trial
involv
larg
number
patient
mandatori
achiev
definit
evid
prevent
cur
role
probiot
medic
practic
gastrointestin
gi
tract
start
mouth
involv
oesophagu
stomach
small
larg
intestin
end
anu
fig
gi
tract
four
main
function
ingest
digest
absorpt
defec
normal
human
adult
male
gi
tract
approxim
long
divid
upper
tract
made
mouth
pharynx
oesophagu
stomach
lower
tract
made
small
intestin
duodenum
jejunum
ileum
larg
intestin
cecum
colon
rectum
anu
aerob
anaerob
bacteria
yeast
fungi
live
gi
tract
surfac
area
organ
healthi
intestin
tract
live
natur
balanc
call
symbiosi
speci
commens
bacteri
organ
within
bodi
vast
major
gut
fact
mammalian
gut
consid
one
dens
popul
ecosystem
earth
bacteri
load
region
organismsg
fecal
materi
larg
intestin
sever
speci
microorgan
adult
human
gut
known
microbiota
may
contain
nearli
time
number
gene
contain
within
human
genom
genom
collect
organ
call
microbiom
longitudin
distribut
intestin
microorgan
increas
densiti
progress
small
bowel
colon
fig
anaerob
bacteria
benefit
host
perform
metabol
function
includ
ferment
provid
shortchain
fatti
acid
scfa
produc
vitamin
ad
trophic
action
epithelium
aid
develop
immun
system
stomach
harbour
bacteria
mainli
acidtoler
lactobacilli
acid
due
gastric
juic
colon
million
time
bacteria
stomach
due
higher
exposur
nutrient
slow
transit
lowredox
potenti
fece
made
bacteria
new
bacteria
produc
old
one
flush
intestin
final
present
fece
differ
strain
bacteria
live
gi
tract
summar
tabl
normal
flora
colon
gi
tract
exert
sever
function
synthes
excret
vitamin
excess
need
absorb
nutrient
host
enter
bacteria
secret
vitamin
k
vitamin
lactic
acid
bacteria
produc
certain
bvitamin
prevent
pathogen
colon
compet
attach
site
essenti
nutrient
like
produc
substanc
inhibit
kill
non
indigen
speci
stimul
develop
certain
tissu
ie
caecum
certain
lymphat
tissu
peyer
patch
gi
tract
stimul
product
natur
antibodi
produc
varieti
substanc
rang
rel
nonspecif
fatti
acid
peroxid
highli
specif
bacteriocin
inhibit
kill
bacteria
gut
microbiota
also
known
influenc
energi
balanc
turn
emerg
evid
demonstr
import
gut
microbiota
pathophysiolog
obes
initi
acquisit
intestin
microbiota
play
key
role
develop
immun
process
protect
pathogen
human
fetu
steril
utero
microb
colon
passag
birth
canal
host
genotyp
import
determin
popul
intestin
organ
birth
influenc
babi
exposur
numer
bacteria
environ
eg
skin
mouth
mother
milk
initi
microbiota
rel
unstabl
chang
initi
period
life
reinhardt
et
al
report
infant
initi
colon
facult
anaerob
enterobacteria
gramposit
cocci
thought
creat
reduc
environ
favor
establish
oblig
anaerob
includ
bacteroid
bifidobacterium
clostridium
tennison
et
al
report
type
birth
deliveri
signific
impact
develop
gut
microbiota
fact
vagin
deliveri
allow
infant
exposur
matern
bacteria
ie
longer
birth
process
greater
exposur
infant
born
cesarean
deliveri
acquir
bacteria
exposur
mother
well
isol
transfer
nurs
staff
infant
air
equip
follow
birth
oral
cutan
bacteria
mother
mechan
transfer
infant
suckl
kiss
caress
moreov
author
observ
breast
feed
expos
infant
bacteria
especi
bifidobacteria
milk
duct
nippl
surround
skin
breast
milk
contain
antimicrobi
compon
growth
factor
stimul
develop
matur
intestin
mucosa
fig
pictur
report
dibais
et
al
gut
microbiota
possibl
relationship
obes
key
physiolog
microbiolog
featur
gut
rel
concentr
bacteria
ph
variou
locat
within
adult
gut
shown
cfu
colonyform
unit
tabl
gi
flora
compon
oral
caviti
saliva
author
conclud
develop
infantil
intestin
microbiota
involv
initi
vagin
exposur
transmiss
neonat
care
subsequ
breast
feed
final
introduct
solid
food
bacteri
profil
breast
formula
fed
infant
becom
similar
adult
year
life
convers
adult
microbiota
gi
tract
bacteria
essenti
normal
physiolog
also
potenti
pathogen
dysbiosi
occur
gi
bacteri
microflora
ecolog
equilibrium
alter
lead
imbal
involv
metabol
immunolog
feedback
host
round
et
al
describ
healthi
microbiota
balanc
composit
mani
class
bacteria
symbiont
organ
known
health
promot
function
commens
perman
resid
provid
benefit
detriment
host
pathobiont
perman
resid
microbiota
potenti
induc
patholog
author
underlin
condit
dysbiosi
unnatur
shift
composit
microbiota
result
either
reduct
number
symbiont
andor
increas
number
pathobiont
fig
condit
lead
mild
subject
discomfort
even
diseas
condit
eg
dysbiosi
lead
nonspecif
inflamm
may
predispos
certain
genet
suscept
peopl
inflammatori
diseas
good
balanc
gi
tract
microflora
respons
lot
function
within
bodi
vitamin
product
hormon
activ
immun
detoxif
process
case
bacteri
imbal
releas
toxic
metabol
product
induc
follow
flatul
bloat
intestin
pain
inflamm
cramp
constip
andor
diarrhea
import
correct
dysbiosi
diagnosi
made
treatment
symptom
lead
solv
real
problem
bring
patient
develop
diseas
fact
intestin
dysbiosi
consid
possibl
caus
contribut
factor
patient
asthma
bronchiti
allergi
autoimmun
disord
breast
colon
cancer
unexplain
fatigu
neuropsychiatr
symptom
system
effect
halitosi
adren
stress
diarrhea
candida
leaki
gut
syndrom
colon
cancer
breast
cancer
consid
consequ
dysbiosi
possibl
factor
contribut
dysbiosi
host
genet
lifestyl
exposur
microorgan
medic
practic
diet
stress
birth
steril
environ
hospit
protect
exposur
danger
pathogen
also
prevent
earli
exposur
health
promot
bacteria
overus
vaccin
antibiot
distinguish
pathogen
symbiot
microorgan
could
advers
alter
microbiota
mani
chronic
degen
diseas
irrit
bowel
syndrom
ib
inflammatori
bowel
diseas
ibd
rheumatoid
arthriti
ankylos
spondyl
consid
today
link
abnorm
bacteria
microflora
ecolog
fig
term
probiot
deriv
greeklatin
word
pro
greek
word
bio
mean
life
concept
probiot
probabl
firstli
introduc
russian
nobel
laureat
eli
metchnikoff
prolong
life
optimist
studi
propos
idea
ingest
microb
could
benefici
effect
human
be
especi
treat
digest
diseas
term
probiot
firstli
use
lilli
stillwel
describ
substanc
secret
one
organ
stimul
growth
anoth
world
health
organ
food
agricultur
organ
unit
nation
defin
probiot
live
microorgan
administ
adequ
amount
confer
health
benefit
host
probiot
consist
bacteria
yeast
consid
function
food
recolon
restor
microflora
symbiosi
intestin
tract
probiot
bacteria
similar
natur
found
peopl
gut
especi
breastf
infant
known
natur
protect
mani
diseas
often
bacteria
come
two
group
lactobacillu
bifidobacterium
group
involv
differ
speci
lactobacillu
acidophilu
bifidobacterium
bifidu
etc
includ
differ
strain
common
probiot
saccharomyc
boulardii
yeast
exampl
bacteria
use
probiot
formul
lactobacillu
acidophilu
lactobacillu
rhamnosu
lactobacillu
bulgaricu
lactobacillu
salivariu
lactobacillu
plantarum
lactobacillu
casei
lactobacillu
sporogen
bifidobacterium
bifidum
bifidobacteria
longum
bifidobacteria
infanti
streptococcu
thermophilu
homeostat
soil
organ
hso
good
probiot
must
possess
follow
requir
abl
adher
cell
exclud
reduc
pathogen
adher
abl
persist
multipli
produc
acid
hydrogen
peroxid
bacteriocin
antagonist
pathogen
growth
abl
safe
noninvas
noncarcinogen
nonpathogen
abl
coaggreg
form
normal
balanc
flora
adequ
amount
health
benefit
dose
billion
colonyform
unit
cfu
recommend
least
day
cfuday
probiot
avail
food
dietari
supplement
exampl
capsul
tablet
powder
form
well
probiot
food
supplement
bacteria
may
present
origin
ad
prepar
probiot
must
surviv
gastric
bile
acid
order
reach
intestin
tract
colon
host
epithelium
exhibit
benefici
effect
convent
form
lactobacillityp
probiot
nonspor
form
therefor
inactiv
bile
low
gastric
ph
addit
probiot
select
commerci
use
must
surviv
industri
manufactur
storag
ensur
longterm
viabil
activ
cell
convent
lactobacilli
die
c
sporebear
lactic
acidform
bacteria
show
decreas
viabl
cell
even
heat
salin
c
min
therefor
surviv
gut
microbiota
shape
intestin
immun
respons
health
diseas
probiot
gi
tract
strongli
affect
stomach
acid
length
exposur
acid
concentr
length
exposur
bile
salt
level
bile
salt
hydrolas
activ
probiot
must
confus
prebiot
nondigest
food
ingredi
select
stimul
growth
andor
activ
benefici
microorgan
alreadi
present
peopl
colon
term
prebiot
first
introduc
gibson
roberfroid
defin
nondigest
food
ingredi
benefici
affect
host
select
stimul
growth
andor
activ
one
limit
number
bacteria
colon
thu
improv
host
health
probiot
prebiot
mix
togeth
form
synbiot
synbiot
supplement
contain
prebiot
probiot
work
togeth
keep
healthi
bacteri
microflora
human
intestin
ferment
milk
yogurt
kefir
consid
true
synbiot
product
function
food
sinc
contribut
restor
normal
bacteri
microflora
also
suppli
food
need
surviv
howev
product
promot
symbiosi
best
synbiot
combin
current
avail
includ
bifidobacteria
fructooligosaccharid
fo
lactobacillu
gg
inulin
bifidobacteria
lactobacilli
fo
inulin
fo
extract
fruit
veget
like
banana
onion
chicori
root
garlic
asparagu
barley
wheat
tomato
onion
rye
garlic
leek
jerusalem
artichok
rel
found
highest
concentr
fo
fo
group
linear
fructos
oligom
oligosaccharid
abl
escap
digest
human
upper
intestin
reach
colon
total
ferment
mostli
lactat
scfa
acet
propion
butyr
ga
like
dietari
fibr
consequ
ferment
calor
valu
approxim
kcalg
fecal
bulk
effect
fo
observ
human
import
properti
scfo
stimul
bifidobacteri
growth
fo
chemic
structur
made
recogn
enzym
bfructosidas
typic
bifidobacteria
easili
metabol
pathogen
putrefact
bacteria
abl
break
fo
chemic
bond
make
select
util
oligosaccharid
specif
suppress
growth
potenti
harm
speci
clostridium
perfringen
colon
prebiot
effect
scfo
dose
depend
chain
length
relat
associ
decreas
fecal
ph
increas
fecal
colon
organ
acid
decreas
product
nitrogen
end
product
urin
stool
decreas
fecal
bacteri
enzymat
activ
modif
fecal
neutral
sterol
scfo
enhanc
magnesium
absorpt
human
shown
anim
model
reduc
colon
tumour
develop
enhanc
colon
butyr
concentr
local
immun
system
effector
buddington
et
al
studi
effect
dietari
fo
healthi
adult
human
subject
fed
control
diet
day
g
neosugard
day
fo
caus
bglucoronidas
glycochol
acid
hydrolas
activ
decreas
respect
author
found
g
neosugard
alter
fecal
flora
benefici
way
decreas
activ
reduct
enzym
william
et
al
determin
chang
abund
select
bacteria
anaerob
fecal
sampl
adult
human
volunt
consum
g
neosugar
mixtur
scfo
nutrilit
product
inc
daili
two
week
presenc
fo
diet
act
increas
growth
host
exist
microbiota
encourag
prolifer
benefici
bacteria
group
lactobacilli
bifidobacteria
bornet
et
al
report
vitro
vivo
studi
anim
human
demonstr
fo
good
substrat
bifidobacteria
spp
possess
bfructoisidas
bacteroid
spp
bad
substrat
e
coli
c
perfrigen
fo
feed
also
relat
increas
bifidobacteria
lactobacilli
decreas
c
perfrigen
bifidobacteria
respons
acet
acid
lactic
acid
product
reduc
intestin
ph
ph
reduct
restrict
prohibit
growth
mani
potenti
pathogen
putrefact
bacteria
reduct
enzym
activ
stool
nitroreductas
decarboxylas
etc
deep
impact
metabol
carcinogen
substanc
nnitroso
compound
phenol
product
tyrosin
tryptophan
metabolit
biliari
steroid
conclus
fo
abl
act
bifidobacteria
could
protect
factor
colon
cancer
hidaka
et
al
perform
sever
clinic
studi
base
administr
fo
conclud
compound
respons
cholesterol
reduct
reduct
ldl
cholesterol
content
suppress
putrefact
normal
colon
microbi
disord
allevi
constip
author
underlin
use
seem
strictli
relat
prolifer
bifidobacteria
saccahrolyt
intestin
bacteria
scfa
produc
organ
well
hidaka
et
al
perform
clinic
studi
use
neosugar
g
prepar
sucros
action
enzym
bfructofuranosidas
produc
aspergillu
niger
neosugar
mixtur
fo
purifi
neosugar
g
remov
monosaccharid
disaccharid
resin
treatment
appli
food
contain
neosugar
jelli
drink
also
prepar
clinic
studi
clinic
studi
show
fo
administr
improv
blood
lipid
hyperlipidemia
suppress
product
intestin
putrefact
substanc
improv
intestin
flora
relief
constip
aumenta
et
al
report
nondigest
oligosaccharid
ndo
found
stimul
absorpt
sever
miner
improv
miner
bone
scientif
evid
function
effect
ndo
base
anim
experi
ndo
increas
avail
calcium
magnesium
zinc
iron
stimulatori
effect
ndo
assum
mainli
due
prebiot
charact
prebiot
inulin
oligofructos
glucooligosaccharid
galactooligosaccharid
found
stimul
absorpt
retent
sever
miner
particularli
magnesium
calcium
iron
find
obtain
studi
perform
rat
number
studi
effect
ndo
miner
metabol
human
limit
posit
effect
calcium
absorpt
seem
occur
condit
increas
calcium
requir
adolesc
postmenopaus
fig
word
probiot
refer
microorgan
abl
confer
health
benefit
human
industri
prepar
nutrit
pharmaceut
use
consumpt
product
grow
fast
world
probiot
gener
consid
gener
regard
safe
gra
indu
et
al
suggest
probiot
respons
competit
exclus
enter
pathogen
gut
lumen
put
inhibitori
mechan
product
lactic
acid
bacteriocin
moreov
restor
normal
intestin
flora
antibiot
therapi
trigger
cytokin
synthesi
enterocyt
attach
surfac
produc
toxic
metabolit
like
hydrogen
peroxid
synthes
butyr
acid
increas
turnov
enterocyt
neutral
dietari
carcinogen
probiot
exert
sever
immunomodulatori
function
act
cellular
humor
respons
furthermor
stimul
type
helper
cell
l
casei
mononuclear
cell
lead
increas
clearanc
circul
pathogen
bacteria
l
acidophilu
macrophag
produc
tnfalpha
product
increas
clearanc
circul
pathogen
bacteria
kupffer
cell
produc
antirotavir
iga
antinfluenza
igg
antibodi
b
breve
snydman
report
three
theoret
concern
regard
safeti
probiot
firstli
occurr
diseas
due
bacteremia
sepsi
endocard
secondli
toxic
metabol
effect
gi
tract
thirdli
transfer
antibiot
resist
gi
flora
author
underlin
although
rare
case
bacteremia
fungemia
relat
use
saprophyt
probiot
epidemiolog
evid
clinic
trial
epidemiolog
survey
suggest
safe
use
wassenaar
et
al
highlight
bacteria
use
probiot
formul
complet
safe
although
could
flaw
sometim
virul
factor
detect
probiot
bacteri
strain
horizont
gene
transfer
result
acquisit
virul
gene
antimicrobi
resist
probiot
bacteria
antimicrobi
resist
bacteria
possibl
aid
spread
unwant
resist
endogen
bacteri
popul
liong
et
al
observ
bacteria
strain
commonli
use
probiot
formul
lactobacillu
leuconostoc
pediococcu
enterococcu
bifidobacterium
isol
infect
site
lead
problem
probiot
transloc
author
underlin
probiot
transloc
hardli
occur
healthi
human
happen
detriment
effect
rare
healthdamag
effect
probiot
transloc
occur
immunocompromis
patient
peopl
probiot
might
theoret
caus
infect
need
treat
antibiot
unfortun
antibiot
resist
strain
increas
complex
erad
sure
investig
requir
analyz
mechan
probiot
transloc
infect
safeti
assess
focus
mechan
neg
effect
probiot
outweigh
benefit
lammer
et
al
studi
mucos
gene
express
pleiotrop
proinflammatori
cytokin
interleukin
il
cytokin
interferongamma
ifngamma
tnfalpha
regulatori
cytokin
transform
growth
factorbeta
chemokin
addit
assess
cytokin
gene
express
presenc
polymorphonuclear
cell
mucos
tissu
evalu
patient
treat
probiot
signific
lower
mucos
mrna
express
level
ifngamma
compar
placebotr
patient
lower
number
polymorphonuclear
cell
present
tissu
patient
within
probiot
group
compar
number
polymorphonuclear
cell
tissu
patient
receiv
placebo
patient
episod
pouchiti
studi
highlight
probiot
treatment
abl
regul
mucos
immun
respons
reduc
mucos
level
neutrophilchemoattract
tissu
influx
polymorphonuclear
cell
may
act
inhibit
cell
activ
reinforc
barrier
function
keep
tight
control
potent
proinflammatori
cytokin
random
doubleblind
studi
design
marchan
et
al
probiot
bacteria
placebo
administ
month
deliveri
mother
month
infant
famili
histori
allergi
plasma
sampl
analyz
creactiv
protein
crp
total
iga
ige
foodspecif
iga
igg
ige
tnfalpha
ifngamma
associ
crp
decreas
risk
eczema
year
age
allergypron
children
support
idea
chronic
lowgrad
inflamm
protect
eczema
lowgrad
inflamm
induc
probiot
character
elev
ige
iga
chang
typic
observ
helminth
infect
associ
induct
regulatori
mechan
studi
emphas
role
chronic
microbi
exposur
immun
modul
protect
allergi
stadbauer
et
al
openlabel
studi
involv
patient
alcohol
cirrhosi
lactobacillu
casei
shirota
lc
time
daili
week
healthi
control
cirrhot
patient
receiv
probiot
report
probiot
restor
neutrophil
phagocyt
capac
cirrhosi
possibl
chang
secret
express
warrant
larger
random
control
mechanist
studi
kekkonen
et
al
evalu
effect
stimul
provid
sever
probiot
bacteri
strain
streptococcu
lactobacillu
bifidobacterium
lactococcu
leuconostoc
propionibacterium
cytokin
product
human
peripher
blood
mononuclear
cell
pbmc
probiot
thermophilu
leuconostoc
strain
shown
potent
induc
type
cytokin
ifngamma
probiot
lactobacillu
strain
use
bacteri
combin
result
enhanc
cytokin
product
first
studi
investig
effect
probiot
intervent
global
lipidom
profil
human
design
kekkonen
et
al
studi
investig
effect
three
week
intervent
lactobacillu
rhamnosu
global
serum
lipidom
profil
evalu
whether
chang
inflammatori
variabl
crp
tnfalpha
reflect
global
lipidom
profil
healthi
adult
author
observ
probiot
lactobacillu
rhamnosu
intervent
may
lead
chang
serum
global
lipid
profil
reflect
decreas
glycerophosphatidylcholin
gpcho
lysophosphatidylcholin
lysogpcho
sphingomyelin
sm
increas
triacylglycerol
tag
among
inflammatori
variabl
moder
associ
chang
global
lipidom
profil
toprank
lipid
associ
proinflammatori
lysogpcho
weak
associ
lipidom
profil
two
inflammatori
marker
tnfalpha
takeda
et
al
placebocontrol
crossov
trial
observ
effect
lc
natur
killer
nk
cell
activ
human
nk
cell
activ
exhibit
declin
trend
period
placebo
ingest
nk
cell
activ
increas
intak
ferment
milk
contain
live
lc
week
human
pbmc
cultur
presenc
heatkil
lc
nk
cell
activ
enhanc
abil
lc
enhanc
nk
cell
activ
induc
product
correl
addit
monoclon
antibodi
reduc
enhanc
nk
cell
activ
trigger
lc
addit
separ
nk
cell
lcsstimul
monocyt
membran
filter
reduc
nk
cell
activ
intermedi
level
almost
depriv
monocyt
abil
produc
author
demonstr
lc
enhanc
nk
cell
activ
vivo
vitro
human
may
respons
enhanc
nk
cell
activ
trigger
lc
chang
composit
gut
microbiota
implic
pathogenesi
allerg
disord
suggest
benefici
interact
intestin
immun
system
specif
bacteri
strain
ivori
et
al
design
doubleblind
placebocontrol
studi
season
allerg
rhiniti
sar
suffer
group
author
observ
volunt
treat
lc
show
signific
reduct
level
antigeninduc
ifngamma
product
compar
volunt
supplement
placebo
meanwhil
level
specif
igg
increas
ige
one
decreas
probiot
group
chang
antigeninduc
product
cytokin
observ
patient
treat
probiot
show
probiot
supplement
modul
immun
respons
sar
may
potenti
allevi
sever
symptom
twetman
et
al
randomli
assign
fortytwo
healthi
adult
moder
level
gingiv
inflamm
one
three
parallel
arm
group
ap
given
one
activ
one
placebo
gum
daili
group
aa
receiv
two
activ
chew
gum
group
pp
two
placebo
gum
chew
gum
contain
two
strain
lactobacillu
reuteri
atcc
atcc
pta
cfu
gum
respect
author
observ
reduct
proinflammatori
cytokin
level
tnfalpha
decreas
significantli
p
group
aa
compar
baselin
week
respect
gingiv
crevicular
fluid
point
probiot
approach
fight
inflamm
oral
caviti
skin
abl
act
physic
barrier
exert
sever
function
fluid
homeostasi
thermoregul
immunolog
function
neurosensori
function
metabol
function
primari
protect
infect
case
thermal
injuri
burn
colon
sever
type
pathogen
ie
primarili
gramposit
bacteria
methicillinresist
staphylococcu
aureu
mrsa
gramneg
bacteria
acinetobact
baumanniiecalcoaceticu
complex
pseudomona
aeruginosa
klebsiella
speci
fungal
pathogen
prevent
infect
includ
earli
burneschar
excis
topic
prophylact
antibiot
aggress
infectioncontrol
measur
antimicrobi
resist
bacteria
isol
patient
burn
increas
bacteri
colon
infect
remain
major
caus
delay
heal
graft
reject
follow
burn
topic
treatment
necessari
reduc
incid
burn
wound
infect
abil
probiot
organ
lactobacillu
plantarum
inhibit
pathogen
activ
pseudomona
aeruginosa
vitro
vivo
test
et
al
vitro
lactobacillu
plantarum
whole
cultur
cultur
filtrat
acid
filtrat
neutralis
acid
filtrat
isol
wash
cell
test
effect
product
p
aeruginosa
quorumsens
signal
molecul
acylhomoserinelacton
ahl
two
virul
factor
control
signal
molecul
elastas
biofilm
inhibit
l
plantarum
cultur
filtrat
isol
wash
cell
acid
l
plantarum
growth
medium
inhibitori
activ
greatest
activ
exert
whole
cultur
vivo
burnedmous
model
use
burn
infect
p
aeruginosa
treat
l
plantarum
day
postinfect
sampl
skin
liver
spleen
taken
day
demonstr
l
plantarum
inhibit
p
aeruginosa
colon
also
improv
tissu
repair
enhanc
phagocytosi
p
aeruginosa
produc
tissu
phagocyt
decreas
apoptosi
day
author
conclud
l
plantarum
andor
byproduct
potenti
therapeut
agent
local
treatment
p
aeruginosa
burn
infect
peral
et
al
cultur
l
plantarum
de
man
rogosa
sharp
medium
provid
altern
method
burn
treatment
use
silver
sulphadiazin
sdag
microbicid
agent
control
eighti
burn
patient
plastic
surgeri
burn
unit
group
infect
delay
secondand
thirddegre
non
infect
earli
thirddegre
burn
treat
l
plantarum
sdag
proport
patient
delay
seconddegre
burn
l
plantarum
sdag
rel
rate
comparison
decreas
bacteri
load
bacteriag
tissu
promot
granul
tissu
wound
bed
heal
earli
thirddegre
burn
valu
l
plantarum
sdag
rel
rate
prevent
wound
infect
promot
granul
tissu
graft
take
treatment
rel
rate
l
plantarum
sdag
rel
rate
heal
delay
thirddegre
burn
valu
l
plantarum
sdag
rel
rate
compar
decreas
bacteri
load
bacteriag
tissu
provid
granul
tissu
wound
bed
graft
take
treatment
rel
rate
l
plantarum
sdag
rel
rate
heal
studi
suggest
l
plantarum
treatment
could
valid
therapi
topic
treatment
burn
probiot
formul
wide
studi
treatment
atop
dermat
ad
type
eczema
patholog
defin
inflammatori
chronic
relaps
noncontagi
prurit
skin
diseas
associ
elev
ige
level
respons
ad
anim
model
human
studi
investig
use
differ
probiot
differ
strain
bifidobacterium
lactobacillu
lactococcu
sever
anim
studi
involv
use
probiot
observ
suppress
specif
nonspecif
ige
product
reduct
infiltr
eosinophil
degranul
mast
cell
potenti
regulatori
cell
cytokin
tgfbeta
rel
potenti
activ
along
reduc
symptom
ad
sever
welldesign
doubleblind
placebocontrol
human
studi
show
probiot
strain
administ
perinat
period
prevent
occurr
ad
consist
show
reduct
specif
nonspecif
ige
chang
specif
immunomodulatori
cytokin
administr
select
strain
probiot
perinat
period
may
help
prevent
ad
guenich
et
al
design
prospect
doubleblind
placebocontrol
clinic
studi
cream
contain
lysat
nonpathogen
bacteria
vitreoscilla
filiformi
seventyf
volunt
ad
year
age
random
receiv
either
v
filiformi
cream
vehicl
cream
daili
day
therapi
efficaci
evalu
follow
paramet
score
atop
dermat
scorad
transepiderm
water
loss
tewl
assess
microflora
patient
assess
itch
loss
sleep
v
filiformi
lysat
significantli
decreas
scorad
level
p
pruritu
p
activ
cream
significantli
decreas
loss
sleep
day
day
p
v
filiformi
lysat
reduc
staphylococcu
aureu
colon
skin
skin
barrier
determin
tewl
also
improv
significantli
cream
alon
v
filiformi
lysat
significantli
improv
ad
may
part
due
reduct
aureu
seem
concern
part
direct
immunomodulatori
effect
skinassoci
immun
respons
zuccotti
et
al
analyz
possibl
caus
relat
increas
diagnosi
allergi
relat
diseas
last
year
notic
firstli
reduc
microbi
stimul
infanc
earli
childhood
result
slower
postnat
matur
immun
system
develop
optim
balanc
immun
hygien
hypothesi
secondli
alter
microflora
promot
persist
cytokin
predomin
birth
prevent
shift
toward
respons
ifngamma
product
go
report
sever
studi
involv
use
probiot
formul
evalu
efficaci
treatment
allerg
diseas
base
abil
chang
either
composit
andor
metabol
activ
microbiota
modul
immun
system
reactiv
way
benefit
health
wicken
et
al
design
doubleblind
random
placebocontrol
studi
pregnant
women
random
take
lactobacillu
rhamnosu
l
rhamnosu
bifidobacterium
animali
subsp
lacti
strain
placebo
daili
week
gestat
month
breastfeed
infant
random
receiv
treatment
birth
year
n
infant
cumul
preval
eczema
point
preval
atopi
use
skin
prick
test
common
allergen
assess
year
infant
receiv
l
rhamnosu
significantli
p
reduc
risk
eczema
hazard
ratio
hr
ci
compar
placebo
case
b
animali
subsp
lacti
hr
ci
signific
effect
l
rhamnosu
hr
ci
b
animali
subsp
lacti
hr
ci
atopi
l
rhamnosu
like
b
animali
subsp
lacti
present
fece
month
although
detect
rate
similar
month
author
conclud
supplement
l
rhamnosu
b
animali
subsp
lacti
substanti
reduc
cumul
preval
eczema
atopi
year
abrahamsson
perform
doubleblind
random
placebocontrol
trial
involv
famili
allerg
diseas
mother
receiv
l
reuteri
atcc
cfu
daili
gestat
week
deliveri
babi
continu
product
birth
month
age
follow
anoth
year
assess
oral
administr
probiot
l
reuteri
may
allevi
even
prevent
eczema
infant
famili
histori
allerg
diseas
cumul
incid
eczema
similar
treat
versu
placebo
group
howev
l
reuteri
group
less
igeassoci
eczema
second
year
versu
p
skin
prick
test
reactiv
also
less
common
treat
placebo
group
significantli
infant
mother
allergi
versu
p
wheez
potenti
allerg
diseas
affect
author
conclud
treat
infant
less
igeassoci
eczema
year
age
therefor
possibl
ran
reduc
risk
develop
later
respiratori
allerg
diseas
therefor
probiot
may
reduc
incid
igeassoci
eczema
infanc
kukkonen
et
al
studi
effect
mixtur
probiot
bacteri
strain
lactobacillu
rhamnosu
gg
atcc
l
rhamnosu
dsm
bifidobacterium
breve
dsm
propionibacterium
freudenreichii
ssp
shermanii
js
dsm
along
prebiot
galactooligosaccharid
prevent
allerg
diseas
one
thousand
two
hundr
twenti
three
pregnant
women
carri
highrisk
children
random
use
probiot
prepar
placebo
week
deliveri
infant
receiv
probiot
plu
galactooligosaccharid
n
placebo
n
month
probiot
treatment
compar
placebo
show
effect
cumul
incid
allerg
diseas
tend
reduc
igeassoci
atop
diseas
odd
ratio
ci
p
probiot
treatment
reduc
eczema
ci
p
atop
eczema
ci
p
lactobacilli
bifidobacteria
frequent
p
colon
gut
supplement
infant
probiot
treatment
show
effect
incid
allerg
diseas
infant
age
significantli
prevent
eczema
especi
atop
eczema
author
observ
invers
associ
atop
diseas
colon
gut
probiot
conclud
prevent
atop
eczema
highrisk
infant
possibl
modul
infant
gut
microbiota
probiot
prebiot
postop
complic
gi
surgeri
could
involv
bacteremia
infecti
complic
main
caus
could
transloc
gi
bacteria
toxin
consequ
bacteri
overgrowth
loss
intestin
epitheli
integr
immunolog
compromis
host
probiot
could
good
candid
fight
factor
competit
potenti
pathogen
nutrient
enterocyt
adhes
site
degrad
toxin
product
antimicrobi
factor
local
system
immunomodul
aim
short
paragraph
report
import
clinic
trial
could
help
evalu
use
probiot
action
eas
complic
rate
patient
undergo
surgeri
gi
tract
main
import
procedur
relat
use
probiot
first
ileal
pouchan
anastomosi
ipaa
involv
remov
entir
colon
rectum
preserv
anu
sphincter
muscl
perform
avoid
perman
stoma
open
collect
wast
case
entir
colon
rectum
need
remov
usual
patient
chronic
ulcer
coliti
patholog
associ
colon
cancer
second
pancreaticoduodectomi
treat
tumor
pancreat
head
neck
uncin
process
third
surgic
resect
patient
local
tumor
affect
pancrea
falk
et
al
analyz
possibl
role
probiot
treatment
pouchiti
inflamm
ileal
reservoir
major
complic
ipaa
follow
proctocolectomi
ulcer
coliti
uc
review
report
patient
pouchiti
increas
number
anaerob
aerob
less
bifidobacteria
anaerob
lactobacilli
clostridia
patient
affect
condit
author
report
doubleblind
studi
patient
chronic
pouchiti
treat
vsl
probiot
bacteri
mix
contain
lactobacilli
strain
three
bifidobacteria
strain
one
streptococcu
strain
show
probiot
prevent
relaps
pouchiti
anoth
studi
combin
lactobacillu
rhamnosu
fo
confirm
possibl
use
probiot
formul
induc
remiss
condit
pronio
et
al
report
vsl
administr
patient
ipaa
modul
pouchiti
diseas
activ
score
expand
number
mucos
regulatori
cell
openlabel
studi
patient
without
sign
symptom
pouchiti
random
differ
period
surgeri
sachet
vsl
daili
treatment
month
particular
author
observ
signific
reduct
pdai
score
signific
increas
percentag
mucos
high
cell
compar
baselin
valu
tissu
sampl
differ
point
show
signific
reduct
mrna
express
signific
increas
mrna
express
ray
et
al
design
prospect
random
monocentr
doubleblind
trial
involv
patient
follow
pyloruspreserv
pancreatoduodenectomi
pppd
group
receiv
composit
lactobacilli
fiber
group
b
receiv
placebo
fiber
start
day
surgeri
continu
day
studi
prove
earli
enter
nutrit
supplement
mixtur
lactobacilli
fiber
reduc
bacteri
infect
rate
antibiot
therapi
follow
pppd
nomura
et
al
randomli
alloc
seventi
patient
pancreaticobiliari
diseas
two
group
first
group
receiv
probiot
second
serv
control
pancreaticoduodenectomi
probiot
use
studi
contain
enterococcu
faecali
clostridium
butyricum
toa
bacillu
mesentericu
toa
first
administ
immedi
admiss
day
oper
reintroduc
second
postop
day
administ
hospit
discharg
studi
show
use
periop
probiot
reduc
postop
infecti
complic
pancreaticoduodenectomi
make
promis
potenti
adjunct
therapi
patient
undergo
highrisk
hepato
biliari
pancreat
surgeri
reddi
et
al
design
studi
ninetytwo
patient
randomli
assign
one
four
group
group
mechan
bowel
prepar
mbp
group
neomycin
mbp
group
synbiot
neomycin
mbp
group
synbiot
neomycin
mbp
chang
gut
microflora
assess
cultur
nasogastr
aspir
polymeras
chain
reaction
pcr
denatur
gradient
gel
electrophoresi
fecal
sampl
intestin
barrier
function
determin
microbiolog
confirm
bacteri
transloc
measur
intestin
permeabl
inflammatori
respons
monitor
measur
serum
crp
septic
morbid
record
prospect
investig
whether
possibl
modul
gut
microflora
preserv
intestin
barrier
function
elect
colorect
surgeri
use
combin
oral
antibiot
synbiot
mbp
author
observ
reduct
inflammatori
respons
septic
morbid
studi
show
combin
mbp
neomycin
synbiot
reduc
preval
fecal
enterobacteriacea
bacteri
transloc
van
gossum
et
al
design
multicent
clinic
trial
evalu
efficaci
oral
administr
probiot
lactobacillu
johnsonii
lal
earli
postop
endoscop
recurr
crohn
diseas
cd
studi
involv
seventi
patient
cd
enrol
prior
elect
ileocaec
resect
randomli
assign
surgeri
daili
treatment
either
nestl
cfu
group
n
placebo
group
b
n
week
author
demonstr
oral
administr
probiot
patient
cd
fail
prevent
earli
endoscop
recurr
week
ileocaec
resect
sugawara
et
al
investig
effect
periop
oral
administr
synbiot
upon
intestin
barrier
function
immun
respons
system
inflammatori
respons
microflora
surgic
outcom
patient
undergo
highrisk
hepatobiliari
resect
patient
biliari
cancer
involv
hepat
hilu
n
random
hepatectomi
group
receiv
postop
enter
feed
synbiot
group
anoth
receiv
preoper
plu
postop
synbiot
group
b
lactulosemannitol
lm
ratio
serum
diamin
oxidas
dao
activ
nk
cell
activ
fecal
microflora
fecal
organ
acid
concentr
determin
hepatectomi
author
conclud
preoper
oral
administr
synbiot
enhanc
immun
respons
attenu
system
postop
inflammatori
respons
improv
intestin
microbi
environ
benefici
effect
like
reduc
postop
infecti
complic
hepatobiliari
resect
biliari
tract
cancer
woodgard
et
al
focus
issu
rouxeni
gastric
bypass
rnygb
surgeri
treatment
morbid
obes
respons
alter
gi
flora
lead
bacteri
overgrowth
dysmotil
author
random
fortyfour
patient
undergo
rnygb
either
probiot
control
group
billion
coloni
lactobacillu
administ
daili
postop
probiot
group
probiot
administr
shown
improv
bacteri
overgrowth
vitamin
avail
weight
loss
rnygb
support
hypothesi
alter
gi
microbiota
influenc
weight
loss
urogenit
infect
caus
sexual
transmiss
women
still
one
import
medic
issu
recurr
urinari
tract
infect
uti
case
caus
uropathogen
e
coli
recurr
bacteri
vaginosi
bv
usual
caus
gardnerella
vaginali
recurr
yeast
vaginosi
usual
caus
candida
albican
predomin
bacteria
urinari
tract
healthi
women
lactobacilli
infect
usual
treat
use
antibiot
effect
decreas
number
lactobacilli
caus
gi
symptom
rais
drug
resist
restor
urinari
tract
natur
barrier
infect
zuccotti
et
al
report
studi
highlight
probiot
could
good
altern
antibiot
therapi
due
qualiti
adher
uroepitheli
cell
produc
inhibitor
pathogen
growth
biosurfact
secret
author
report
oral
lactobacillibas
therapi
viabl
condit
show
bacteria
abl
colon
urinari
tract
enter
colon
reid
et
al
report
daili
intak
probiot
strain
l
rhamnosu
lactobacillu
fermentum
result
asymptomat
bv
patient
revert
normal
lactobacilli
domin
vagin
microflora
author
report
two
studi
regard
bv
firstli
twice
daili
use
hydrogen
peroxid
produc
l
acidophilu
product
call
vivag
six
day
led
improv
compar
none
placebo
group
secondli
yogurt
contain
l
acidophilu
deliv
tampon
pregnant
women
show
treat
bv
prevent
infect
month
followup
reid
et
al
also
report
studi
indic
recurr
uti
reduc
use
one
two
capsul
l
rhamnosu
l
fermentum
replac
recent
freez
dri
place
gelatin
capsul
dosag
per
capsul
vagin
per
week
one
year
side
effect
yeast
infect
author
also
explor
use
probiot
treatment
yeast
vagin
report
l
rhamnosu
l
fermentum
abl
kill
inhibit
adhes
yeast
vagin
cell
moreov
report
crossov
studi
involv
patient
recurr
vagin
treat
eight
ounc
l
acidophilu
supplement
yogurt
daili
six
month
switch
yogurt
free
diet
therapi
result
breakthrough
infect
compar
per
studi
term
czaja
et
al
perform
phase
trial
assess
safeti
toler
lactobacillu
vagin
suppositori
prevent
recurr
uti
involv
premenopaus
women
histori
recurr
uti
random
use
lactobacillu
crispatu
placebo
vagin
suppositori
daili
five
day
sever
advers
event
occur
mild
moder
vagin
discharg
genit
irrit
report
women
studi
arm
seven
women
random
l
crispatu
develop
pyuria
without
associ
symptom
women
high
concentr
vagin
lactobacilli
random
l
crispatu
lactobacillu
jensenii
lactobacillu
gasseri
common
lactobacillu
speci
identifi
stabl
preval
time
accord
studi
l
crispatu
given
vagin
suppositori
minim
side
effect
healthi
women
histori
recurr
uti
although
mild
inflamm
urinari
tract
note
women
anukam
et
al
enrol
women
diagnos
bv
particularli
common
condit
black
women
nigeria
often
caus
mycoplasma
well
atopobium
prevotella
gardnerella
sp
discharg
fishi
odor
sialidas
posit
test
nugent
gram
stain
score
random
receiv
either
two
dri
capsul
contain
l
rhamnosu
l
reuteri
night
day
metronidazol
gel
appli
vagin
twice
day
morn
even
followup
day
show
signific
cure
bv
probiot
lactobacilli
treat
subject
compar
metronidazol
treatment
first
report
effect
cure
bv
use
probiot
lactobacilli
author
conclud
given
correl
bv
hiv
high
risk
latter
nigeria
intravagin
use
lactobacilli
provid
women
selfus
therapi
similar
overthecount
antiyeast
medic
treatment
urogenit
infect
martinez
et
al
design
studi
involv
sixtyfour
brazilian
women
diagnos
bv
randomli
assign
receiv
singl
dose
tinidazol
g
supplement
either
placebo
capsul
capsul
contain
l
rhamnosu
l
reuteri
everi
morn
week
end
treatment
day
probiot
group
significantli
higher
cure
rate
bv
placebo
group
p
addit
accord
gramstain
nugent
score
women
assess
normal
vagin
microbiota
probiot
group
vs
placebo
group
p
studi
show
probiot
lactobacilli
provid
benefit
women
treat
antibiot
infecti
condit
mastromarino
et
al
enrol
thirtynin
women
bv
doubleblind
placebocontrol
clinic
trial
receiv
either
one
lactobacilluscontain
tablet
placebo
daili
day
complet
therapi
patient
lactobacillustr
group
n
free
bv
show
normal
intermedi
vagin
flora
compar
two
patient
free
bv
intermedi
flora
among
placebotr
women
p
two
week
complet
therapi
treatment
success
score
lactobacillustr
patient
compar
one
placebo
group
p
treatment
group
total
number
symptomat
patient
intens
symptom
particular
vagin
malodour
significantli
reduc
followup
visit
previous
report
result
brought
author
conclud
intravagin
administr
exogen
select
strain
lactobacilli
restor
normal
vagin
microbiota
could
use
choic
treatment
bv
larsson
et
al
investig
firstli
supplementari
lactobacilli
treatment
could
improv
initi
cure
rate
vagin
clindamycin
therapi
secondli
lactobacilli
repeat
adjunct
treatment
menstrual
cycl
could
lengthen
time
relaps
initi
cure
hundr
bv
diagnos
women
offer
vagin
clindamycin
therapi
follow
vagin
gelatin
capsul
contain
either
freezedri
lactobacilli
ident
placebo
capsul
day
menstrual
cycl
doubleblind
random
placebocontrol
trial
author
conclud
supplementari
treatment
combin
two
differ
strain
probiot
lactobacilli
improv
efficaci
bv
therapi
first
month
treatment
women
initi
cure
adjunct
treatment
lactobacilli
menstrual
cycl
lengthen
time
relaps
significantli
women
remain
bv
free
end
follow
renal
failur
face
remov
wast
product
excess
fluid
use
mechan
method
call
dialysi
two
form
dialysi
use
medic
practic
hemodialysi
hd
periton
dialysi
pd
hd
cycl
blood
machin
filter
blood
return
bodi
clean
wast
pd
cycl
fluid
abdomen
use
individu
peritoneum
filter
plasma
urem
toxin
level
phenol
pcresol
indican
produc
intestin
bacteri
putrefact
metabolit
accumul
great
degre
fece
hd
patient
effici
reduc
hd
intestin
microflora
derang
hd
patient
see
increas
aerob
bacteria
escherichia
coli
decreas
anaerob
bacteria
bifidobacterium
yangco
et
al
report
success
util
nitazoxanid
probiot
treat
multirecurr
clostridium
difficil
infect
cdi
pd
patient
woman
admit
hypotens
nausea
vomit
attribut
metronidazol
therapi
cdi
third
cdi
treatment
regimen
month
admiss
patient
develop
cdi
start
regimen
nitazoxanid
probiot
assist
reestablish
colon
flora
regimen
well
toler
patient
remain
diseas
free
follow
four
month
later
hida
et
al
demonstr
lebenin
prepar
consist
antibioticresist
lactic
acid
bacteria
administr
oral
abl
reduc
level
fecal
putrefact
metabolit
level
compar
healthi
subject
moreov
plasma
level
indican
also
significantli
decreas
lebenintr
patient
analysi
fecal
microflora
reveal
disturb
composit
microflora
character
overgrowth
aerob
bacteria
restor
normal
oral
administr
lebenin
hd
patient
author
demonstr
oral
administr
lactic
acid
bacteria
urem
patient
effect
reduc
level
urem
toxin
especi
indican
blood
inhibit
bacteri
product
mean
correct
intestin
microflora
taki
et
al
demonstr
oral
administr
b
longum
gastroresist
seamless
capsul
hd
patient
effect
decreas
prehd
serum
level
homocystein
indoxyl
sulfat
tag
reduct
serum
level
homocystein
mainli
attribut
suppli
folat
produc
b
longum
human
intestin
diverticular
diseas
dd
acquir
weaken
colon
wall
rare
ileum
duodenum
caus
protrus
mucosa
submucosa
muscular
wall
pouch
occur
weak
area
wall
blood
vessel
penetr
due
high
pressur
insid
colon
often
involv
primarili
sigmoid
region
colon
term
diverticulosi
refer
aymptomat
condit
term
diverticular
diseas
refer
condit
associ
symptom
term
diverticul
use
indic
inflamm
bowel
wall
report
two
interest
studi
design
tursi
et
al
evidenc
possibl
use
probiot
manag
condit
tursi
et
al
design
studi
investig
whether
balsalazid
novel
oral
administ
prodrug
inert
carrier
molecul
bond
molecul
administr
colon
bacteria
split
balsalazid
releas
activ
colon
minim
system
absorpt
andor
vsl
probiot
mixtur
contain
sever
billion
differ
bacteri
strain
mainli
lactobacillu
bifidobacteria
effect
prevent
diverticul
recurr
thirti
consecut
patient
male
femal
mean
age
year
rang
year
affect
uncompl
diverticul
colon
monitor
obtain
remiss
patient
randomli
assign
one
follow
group
follow
group
balsalazid
g
daili
day
everi
month
plu
vsl
billionsday
day
everi
month
group
b
vsl
alon
billionsday
day
everi
month
primari
endpoint
consid
maintain
remiss
throughout
followup
secondari
endpoint
consid
firstli
assess
overal
score
end
followup
secondli
effect
two
differ
treatment
regard
everi
symptom
assess
author
found
one
group
patient
show
relaps
symptom
month
followup
end
followup
patient
complet
symptomfre
whilst
patient
complain
mild
recurr
symptom
two
group
b
patient
show
relaps
diseas
month
followup
respect
end
followup
patient
complet
symptomfre
patient
complain
mild
recurr
symptom
patient
complain
mild
continu
symptom
side
effect
record
throughout
followup
group
studi
show
combin
probioticantiinflammatori
drug
found
better
probiot
treatment
prevent
relaps
uncompl
diverticul
colon
even
without
statist
signific
tursi
et
al
pilot
studi
design
anoth
studi
assess
four
differ
therapeut
schedul
mesalazin
andor
probiot
abl
prevent
recurr
symptomat
dd
colon
prospect
dosefind
studi
conduct
patient
enrol
open
fashion
mesalazin
mg
daili
group
mesalazin
gr
daymonth
group
mesalazin
mgdaili
l
casei
dg
billionday
day
month
group
mesalazin
gr
l
casei
dg
billionday
daymonth
group
l
casei
dg
billionday
day
month
group
l
seventi
one
patient
complet
studi
sixti
six
patient
symptomfre
month
treatment
group
group
group
group
group
l
four
patient
suspend
treatment
followup
experienc
recurr
symptom
two
develop
diverticul
studi
show
mesalazin
andor
l
casei
seem
effect
maintain
remiss
dd
longtim
author
found
recurr
diseas
complic
patient
suspend
treatment
europ
north
america
ib
estim
incid
sweden
commonli
cite
figur
preval
ib
increas
countri
asiaepacif
region
particularli
countri
develop
economi
ib
mainli
occur
age
estim
preval
ib
children
similar
adult
ib
common
disord
intestin
associ
cramp
stomach
pain
ga
bloat
chang
bowel
habit
ib
character
constip
diarrhea
diarrheapredomin
ib
dib
character
increas
intestin
permeabl
accompani
persist
lowgrad
immun
activ
gut
present
increas
number
lymphocyt
mast
cell
enterochromaffin
cell
normal
condit
gut
epitheli
line
form
rel
imperm
barrier
lumin
content
submucosa
requir
intestin
homeostasi
barrier
determin
complex
protein
compos
junction
complex
tight
junction
tj
apic
organel
epitheli
junction
complex
crucial
format
function
epitheli
barrier
tj
compris
numer
protein
best
character
zonula
occluden
zo
occludin
diarrhea
form
predomin
form
bring
patient
experi
abdomin
pain
visibl
abdomin
distens
bloat
bowel
frequenc
particularli
associ
pain
pain
reliev
bowel
action
rectal
passag
mucou
sensat
incomplet
evacu
spastic
colon
syndrom
ib
variant
mainli
character
constip
constip
ib
variant
let
patient
experi
symptom
except
bowel
frequenc
replac
constip
respons
pain
ib
seem
due
dysfunct
muscl
organ
gi
tract
nerv
control
organ
nerv
run
entir
length
gi
tract
esophagu
anu
muscular
wall
organ
reach
also
spinal
cord
brain
ib
thought
result
interplay
abnorm
gi
tract
movement
increas
awar
normal
bodili
function
chang
nervou
system
commun
brain
gi
tract
although
caus
ib
yet
known
factor
usual
associ
condit
genet
influenc
food
intak
endocrin
imbal
malabsorpt
postop
chang
alter
gi
motil
heighten
sensori
function
intestin
malferment
food
residu
psychosomat
factor
psycholog
morbid
stress
abnorm
ill
behaviour
ib
great
neg
impact
patient
emot
health
qualiti
life
especi
face
diseas
entir
life
symptom
allevi
patient
educ
reassur
dietari
modif
definit
resolut
consid
recent
clinic
trial
treatment
ib
worth
rememb
import
studi
face
vanderhoof
et
al
report
studi
develop
poland
use
l
plantarum
bacterium
abl
synthet
nitric
oxid
import
mediat
gut
motil
may
displac
attach
organ
intestin
mucosa
seem
abl
reduc
inflammatori
compon
associ
ib
studi
result
show
reduct
symptom
abdomin
pain
constip
compar
placebo
author
report
anoth
studi
support
benefici
effect
small
doubleblind
placebocontrol
crossov
studi
children
recalcitr
chronic
recurr
abdomin
pain
childhood
show
signific
reduct
sever
abdomin
pain
patient
compar
result
control
subject
tsuchiya
et
al
realiz
studi
evalu
efficaci
symbiot
contain
bifidobacteria
ml
treatment
ib
author
found
week
treatment
patient
symbiot
abl
significantli
reduc
intens
symptom
ib
omahoni
et
al
realiz
studi
compar
respons
symptom
cytokin
ratio
ib
ingest
probiot
prepar
contain
lactobacillu
bifidobacterium
strain
seventyseven
subject
ib
random
receiv
either
lactobacillu
salivariu
bifidobacterium
infanti
dose
live
bacteri
cell
malt
milk
drink
malt
milk
drink
alon
placebo
week
b
infanti
allevi
symptom
ib
symptomat
respons
associ
normal
ratio
antiinflammatori
proinflammatori
cytokin
suggest
immunemodul
role
organ
disord
furri
et
al
design
studi
base
use
symbiot
contain
bifidobacteria
treat
ib
symbiot
success
treat
patholog
without
evid
advers
event
modul
immunolog
paramet
treatment
base
bifidobacteria
fo
improv
intestin
habit
qualiti
patient
life
tabl
adapt
guslandi
et
al
summar
interest
studi
involv
use
probiot
treatment
ib
hun
et
al
design
control
studi
evalu
effect
probiot
bacillu
coagulan
ib
symptom
bacillu
coagulan
ganeden
biotech
inc
mayfield
height
oh
patent
strain
lactic
acid
produc
bacteria
sustain
low
ph
stomach
acid
becom
activ
intestin
strain
b
coagulan
produc
coagulin
heatstabl
proteasesensit
bacteriocinlik
inhibitori
substanc
activ
gramposit
bacteria
spore
bacillu
resist
heat
hostil
gi
condit
therefor
abl
reach
intestin
germin
prolifer
within
host
b
coagulan
maintain
spore
viabil
year
storag
without
need
refriger
unpublish
commun
ganeden
biotech
inc
mayfield
height
oh
make
particularli
suitabl
commerci
use
random
doubleblind
parallelgroup
placebocontrol
clinic
trial
involv
subject
receiv
either
placebo
b
coagulan
day
week
selfassess
sever
ib
symptom
abdomin
pain
bloat
record
everi
day
week
baselin
valu
significantli
differ
studi
group
withingroup
analysi
conduct
subject
met
rome
ii
criteria
ib
diarrhea
ie
must
month
prior
evalu
total
least
week
necessarili
consecut
abdomin
discomfort
pain
featur
relief
defec
onset
associ
chang
frequenc
stool
onset
associ
chang
appear
stool
individu
organ
gi
condit
diseas
previou
intestin
surgeri
immunodefici
lactos
intoler
pregnant
lactat
exclud
studi
patient
taken
commerci
avail
probiot
medic
within
day
studi
also
exclud
author
obtain
result
improv
baselin
abdomin
pain
bloat
score
b
coagulan
group
statist
signific
weekli
comparison
p
placebo
group
chang
abdomin
pain
score
week
achiev
statist
signific
p
treatmentrel
advers
event
seriou
advers
event
report
studi
period
author
base
previou
describ
result
suggest
patent
b
coagulan
probiot
might
safe
effect
option
relief
abdomin
pain
bloat
patient
ib
result
justifi
design
larger
scale
control
clinic
trial
verifi
find
henck
et
al
perform
clinic
trial
treat
two
hundr
ninetyeight
patient
lower
abdomin
symptom
diagnos
ib
week
compound
symbiopharm
gmbh
herborn
germani
e
coli
product
n
placebo
n
doubleblind
random
fashion
patient
seen
weekli
physician
assess
presenc
core
ib
symptom
abdomin
pain
score
ap
well
gener
symptom
score
gss
use
primari
endpoint
respond
complet
absenc
ib
core
symptom
visit
treatment
result
show
respond
rate
gss
drug
comparison
placebo
p
improv
ap
placebo
p
respons
reach
third
visit
onward
medic
placebo
posthoc
analysi
reveal
signific
differ
efficaci
drug
gender
differ
age
group
author
conclud
probiot
effect
superior
placebo
reduc
typic
symptom
ib
barrett
et
al
aim
determin
whether
l
casei
strain
shirota
yakult
alter
small
intestin
bacteri
overgrowth
sibo
test
lactulos
breath
test
whether
associ
chang
symptom
ib
prior
breath
hydrogen
test
dietari
restrict
minimis
intak
fibr
poorli
absorb
shortchain
carbohydr
advis
h
subject
fast
overnight
patient
consum
g
lactulos
made
ml
solut
water
breath
hydrogen
sampl
collect
baselin
everi
min
least
h
author
recruit
patient
ib
rome
ii
criteria
show
earli
rise
breath
hydrogen
lactulos
erbhal
defin
rise
breath
hydrogen
ppm
greater
baselin
breath
hydrogen
two
consecut
sampl
min
follow
ingest
lactulos
time
first
rise
breath
hydrogen
ppm
record
consum
ml
yakult
daili
wk
lactulos
breath
test
repeat
end
treatment
period
symptom
record
daili
use
cm
visual
analogu
scale
fourteen
patient
complet
studi
revers
erbhal
median
time
first
rise
breath
hydrogen
increas
min
p
signific
improv
symptom
score
probiot
therapi
except
wind
p
patient
commenc
least
moder
symptom
longer
erbhal
end
treatment
show
improv
overal
symptom
score
median
final
score
iqr
reduct
n
greater
extent
persist
erbhal
final
score
reduct
n
p
studi
show
yakult
effect
alter
ferment
pattern
small
bowel
consist
reduc
sibo
loss
erbhal
associ
reduc
symptom
studi
find
need
confirm
random
control
trial
adriulli
et
al
test
efficaci
symbiot
patient
dib
patient
random
prebiot
n
symbiot
formul
contain
lactobacillu
paracasei
flortec
n
primari
efficaci
respond
rate
pain
global
relief
symptom
overal
popul
patient
predomin
diarrhea
n
post
hoc
timetrend
analys
chang
within
treatment
carri
follow
result
obtain
patient
absentmild
pain
amount
symbiot
group
prebiot
group
treatment
week
end
treatment
patient
amelior
wellb
respect
versu
treatment
week
versu
end
treatment
within
treatment
group
patient
absentmild
pain
increas
flortec
prebiot
group
time
trend
analys
signific
flortec
p
dib
flortec
significantli
reduc
bowel
movement
pain
ib
score
author
conclud
flortec
encourag
patient
dib
abl
improv
pain
patient
wellb
even
futur
flortec
compar
inert
placebo
establish
efficaci
major
ib
patient
zeng
et
al
perform
studi
determin
possibl
effect
lactic
acid
bacteria
increas
intestin
permeabl
dib
treatment
last
week
random
singl
blind
placebocontrol
studi
dib
patient
patient
given
either
probiot
ferment
milk
streptococcu
thermophilu
lactobacillu
bulgaricu
lactobacillu
acidophilu
bifidobacterium
longum
milk
beverag
contain
bacteria
clinic
symptom
score
intestin
permeabl
measur
tripl
sugar
test
treatment
small
bowel
permeabl
measur
ratio
lm
recoveri
colon
permeabl
measur
total
mass
sucralos
excret
mg
probiot
treatment
small
bowel
permeabl
decreas
significantli
baselin
p
proport
patient
increas
small
bowel
permeabl
lower
one
baselin
vs
p
howev
colon
permeabl
improv
neither
probiot
group
placebo
group
week
treatment
probiot
significantli
decreas
mean
global
ib
score
compar
baselin
score
ae
vs
ae
p
therefor
shortterm
activ
lactic
acid
bacteria
treatment
dib
improv
mucos
barrier
function
enck
et
al
reanalyz
studi
perform
accord
current
ib
standard
two
hundr
ninetyseven
patient
lower
abdomin
symptom
diagnos
ib
treat
week
compound
prosymbioflor
r
symbiopharm
gmbh
herborn
germani
autolys
cell
cell
fragment
enterococcu
faecali
escherichia
coli
placebo
doubleblind
random
fashion
patient
seen
weekli
physician
assess
presenc
core
ib
symptom
respond
least
gss
ap
report
visit
treatment
respond
rate
gss
drug
comparison
placebo
p
improv
ap
respect
p
number
need
treat
gss
ap
report
kaplanemei
analysi
reveal
mean
respons
time
week
activ
treatment
week
placebo
p
studi
lead
author
conclud
treatment
ib
bacteri
lysat
prosymbioflor
effect
superior
placebo
reduc
typic
symptom
ib
patient
drouaultholowacz
et
al
investig
effici
probiot
dietari
supplement
contain
four
strain
lactic
acid
bacteria
symptom
ib
one
hundr
sixteen
patient
ib
fulfil
rome
ii
criteria
random
parallel
group
doubleblind
studi
receiv
placebo
probiot
combin
cfu
daili
four
week
symptom
monitor
weekli
includ
discomfort
abdomin
pain
stool
frequenc
qualiti
qualiti
life
assess
end
treatment
use
fddqualityoflif
questionnair
studi
show
follow
result
one
hundr
subject
complet
studi
probiot
combin
group
placebo
group
probiot
combin
superior
placebo
reliev
symptom
ib
versu
improv
decreas
abdomin
pain
first
fourth
week
treatment
significantli
higher
probiot
treat
patient
versu
p
interest
find
also
observ
ib
subgroup
lower
pain
score
endpoint
patient
altern
bowel
habit
p
increas
stool
frequenc
constip
subgroup
first
week
probiot
treatment
p
author
conclud
probiot
combin
significantli
superior
placebo
reliev
symptom
ib
despit
appar
high
placebo
respons
interest
find
observ
ib
subgroup
field
abdomin
pain
stool
frequenc
sinn
et
al
random
ib
patient
placebo
n
probiot
group
n
lactobacillu
acidophilu
sdc
two
lactobacilli
obtain
infant
fece
examin
biolog
biochem
characterist
show
abil
surviv
high
acid
medium
contain
bile
acid
potent
probiot
unpublish
data
two
select
strain
freez
dri
microbi
compani
cultur
system
inc
usa
freezedri
bacteria
mix
excipi
pack
capsul
good
manufactur
process
gmp
condit
natur
f
p
korea
studi
excipi
ad
blend
bacteria
achiev
desir
dosag
concentr
cfuml
placebo
capsul
contain
excipi
four
week
treatment
l
acidophilussdc
associ
reduc
score
abdomin
pain
discomfort
compar
baselin
p
percent
reduct
abdomin
pain
discomfort
exceed
placebo
score
probiot
placebo
respect
p
signific
differ
proport
respond
probiot
placebo
group
p
drop
advers
event
either
group
studi
period
bittner
et
al
design
studi
extend
previou
assess
probioticeprebiot
complex
patient
ib
pa
probioticeprebiot
complex
report
associ
reduc
sign
symptom
sever
gi
disord
particularli
ib
probiot
compon
complex
anthrobact
agili
citreu
globiformi
luteu
simplex
acinetobact
calcoaceticu
azotobact
chroococcum
paspali
azospirillum
brasiliens
lipoferum
bacillu
brevi
b
marceran
b
pumilu
b
polymyxa
b
subtili
bacteroid
lipolyticum
b
succinogen
brevibacterium
lipolyticum
b
stationi
kurtha
zopfil
myrothecium
verrucaria
pseudomona
calci
p
dentrifican
p
flourescen
p
glathei
phanerochaet
chrysosporium
streptomyc
fradia
cellulosa
griseoflavu
soilbas
microorgan
sbo
class
etiolog
agent
present
minim
hazard
ordinari
condit
openlabel
partial
control
extens
studi
data
collect
ib
patient
continu
treatment
follow
studi
efficaci
probioticeprebiot
complex
data
collect
approxim
week
end
origin
studi
author
observ
total
patient
enter
extens
complet
approxim
followup
studi
result
control
group
week
crossov
treatment
similar
origin
studi
reduct
ib
subsyndrom
ie
gener
ill
feel
nausea
p
indigestionflatul
p
margin
coliti
p
treatment
associ
continu
reduct
gener
ill
feelingsnausea
week
p
followup
rate
remiss
p
base
result
treatment
probioticeprebiot
complex
seem
option
shortterm
week
longterm
approxim
week
reduct
ib
symptom
guyonett
et
al
analyz
effect
ferment
milk
contain
bifidobacterium
animali
yogurt
strain
ib
multicent
doubleblind
control
trial
test
product
ferment
milk
activia
danon
contain
b
animali
cfu
per
pot
togeth
two
classic
yogurt
starter
thermophilu
l
bulgaricu
cfu
pot
control
product
heattreat
yogurt
contain
nonliv
bacteria
cfupot
test
control
product
without
flavour
similar
appear
colour
textur
tast
serv
correspond
one
pot
contain
g
product
specif
prepar
studi
provid
danon
research
palaiseau
franc
total
primari
care
adult
constipationpredomin
ib
rome
ii
random
consum
week
either
test
ferment
milk
heattreat
yogurt
control
hrqol
digest
symptom
assess
week
intentiontotreat
popul
subject
previous
describ
result
brought
author
follow
result
hrqol
discomfort
score
primari
endpoint
improv
p
group
week
respond
rate
hrqol
discomfort
score
higher
vs
p
higher
decreas
bloat
score
ae
sd
vs
ae
p
week
test
vs
control
group
subject
stoolsweek
stool
frequenc
increas
p
week
test
vs
control
group
studi
suggest
benefici
effect
probiot
food
discomfort
hrqol
score
bloat
constipationpredomin
ib
stool
frequenc
subject
stoolsweek
conclus
present
largescal
studi
strongli
suggest
benefici
effect
probiot
food
contain
b
animali
hrqol
discomfort
score
bloat
also
stool
frequenc
subject
stool
per
week
studi
aim
confirm
result
obtain
elucid
mechan
effect
special
interest
provid
addit
scientif
evid
support
use
probiot
food
allevi
ib
symptom
improv
hrqol
discomfort
gawro
nska
et
al
evalu
efficaci
l
rhamnosu
gg
treat
function
abdomin
pain
disord
fapd
children
total
children
fulfil
rome
ii
criteria
function
dyspepsia
fd
ib
function
abdomin
pain
fap
enrol
doubleblind
random
control
trial
receiv
l
rhamnosu
gg
n
placebo
n
week
patient
l
rhamnosu
gg
group
like
treatment
success
pain
placebo
group
vs
rel
benefit
rb
ci
number
need
treat
nnt
ci
children
ib
n
l
rhamnosu
gg
group
like
treatment
success
placebo
group
vs
rb
ci
nnt
ci
reduc
frequenc
pain
p
pain
sever
p
fd
group
n
fap
group
n
differ
found
author
conclud
l
rhamnosu
gg
appear
moder
increas
treatment
success
particularli
among
children
ib
fanigliulo
et
al
aim
investig
efficaci
rifaximin
broadspectrum
poorli
absorb
antibiot
associ
probiot
strain
b
longum
reduc
symptom
patient
ib
perform
monocentr
prospect
random
open
trial
includ
patient
random
two
group
group
patient
receiv
rifaximin
cp
bid
ten
day
month
follow
formul
probiot
strain
b
longum
one
granul
suspens
day
altern
week
group
b
patient
receiv
rifaximin
cp
bid
ten
day
month
clinic
evalu
perform
admiss
take
account
method
visual
analogu
author
observ
followup
group
patient
report
greater
improv
symptom
compar
patient
group
b
p
even
physician
opinion
confirm
result
p
previous
report
result
show
increas
colon
mean
b
longum
cyclic
administr
rifaximin
erad
bacteri
overgrowth
small
intestin
may
reduc
symptom
especi
relat
bowel
habit
stool
frequenc
patient
ib
abnorm
observ
colon
flora
ib
suggest
fact
probiot
approach
ultim
justifi
colecchia
et
al
perform
studi
evalu
efficaci
safeti
symbiot
consist
probiot
b
longum
short
chain
oligosaccharid
prebiot
fo
actilight
patient
constipationvari
ib
six
hundr
thirti
six
patient
men
women
diagnos
constipationtyp
ib
accord
rome
ii
criteria
enrol
center
receiv
symbiot
dose
gdie
least
day
valid
questionnair
investig
symptom
stool
frequenc
administ
treatment
result
base
patient
respons
visual
scale
item
frequenc
increas
significantli
treatment
symptom
class
bloat
abdomin
pain
p
severest
symptom
class
moderatesever
symptom
frequenc
drop
significantli
bloat
abdomin
pain
respect
stool
frequenc
significantli
increas
ae
timesweek
ae
timesweek
author
conclud
studi
product
increas
stool
frequenc
patient
constipationvari
ib
reduc
abdomin
pain
bloat
one
moderatesever
symptom
whorwel
et
al
assess
efficaci
probiot
bacteria
b
infanti
largescal
multicent
clinic
trial
women
ib
determin
optim
dosag
probiot
administr
encapsul
formul
week
baselin
primari
care
ib
patient
bowel
habit
subtyp
random
either
placebo
freezedri
encapsul
b
infanti
dose
cfuml
wk
ib
symptom
monitor
daili
score
likert
scale
primari
outcom
variabl
abdomin
pain
discomfort
composit
symptom
score
subject
global
assess
ib
symptom
relief
measur
qualiti
life
use
ibsqol
instrument
also
record
author
report
follow
result
b
infanti
dose
cfu
significantli
superior
placebo
bifidobacterium
dose
primari
efficaci
variabl
abdomin
pain
well
composit
score
score
bloat
bowel
dysfunct
incomplet
evacu
strain
passag
ga
end
week
studi
improv
global
symptom
assess
exceed
placebo
p
two
dose
probiot
significantli
differ
placebo
dose
associ
signific
formul
problem
signific
advers
event
record
author
conclud
b
infanti
probiot
specif
reliev
mani
symptom
ib
dosag
level
cfu
deliv
capsul
make
stabl
conveni
administ
amen
widespread
use
lack
benefit
observ
dosag
level
probiot
highlight
need
clinic
data
final
dosag
form
dose
probiot
product
use
practic
ibd
commonli
refer
two
chronic
inflammatori
diseas
gi
tract
uc
cd
main
differ
cd
uc
locat
natur
inflammatori
chang
cd
affect
part
gi
tract
mouth
anu
although
major
case
start
termin
ileum
uc
affect
colon
rectum
microscop
uc
restrict
mucosa
cd
affect
whole
bowel
wall
world
gastroenterolog
organ
report
uc
incid
increas
western
countri
sinc
second
world
war
lowincid
area
eastern
europ
asia
develop
countri
cd
incid
per
asia
south
america
per
southern
europ
south
africa
per
new
zealand
australia
per
canada
per
usa
base
data
olmst
counti
minnesota
pathogenesi
ibd
complet
understood
genet
environment
factor
alter
lumin
bacteria
enhanc
intestin
permeabl
play
role
dysregul
intestin
immun
lead
gi
injuri
abnorm
activ
mucos
immun
system
driven
presenc
intestin
microbiota
genet
predispos
patient
seem
play
key
role
patholog
especi
cd
intestin
microbiota
strongli
suspect
play
role
initi
trigger
immun
system
lead
characterist
inflamm
furri
et
al
use
synbiotc
combin
probiot
b
longum
isol
healthi
rectal
epithelium
prebiot
synergi
preferenti
inulinoligofructos
growth
substrat
probiot
strain
treat
uc
patient
treatment
employ
doubl
blind
random
control
trial
use
patient
activ
uc
period
one
month
clinic
statu
score
rectal
biopsi
collect
treatment
transcript
level
epithelium
relat
immun
marker
measur
author
conclud
shortterm
synbiot
treatment
activ
uc
result
improv
full
clinic
appear
chronic
inflamm
patient
receiv
therapi
sokol
et
al
determin
composit
mucosaassoci
microbiota
cd
patient
time
surgic
resect
month
later
use
fish
analysi
found
reduct
major
member
firmicut
faecalibacterium
prausnitzii
associ
higher
risk
postop
recurr
ileal
cd
studi
conduct
part
doubleblind
control
trial
compar
effici
probiot
l
johnsonii
strain
placebo
decreas
endoscop
recurr
cur
surgeri
cd
although
whole
human
trial
includ
patient
present
studi
includ
subset
patient
f
prausnitzii
dsm
isol
human
fecal
stool
grown
c
lyhbhi
medium
braineheart
infus
medium
supplement
yeast
extract
difco
mgl
hemin
supplement
cellobios
mgml
sigmaealdrich
maltos
mgml
sigma
cystein
mgml
sigma
anaerob
chamber
lower
proport
f
prausnitzii
resect
ileal
crohn
mucosa
also
associ
endoscop
recurr
month
author
observ
antinflammatori
effect
vitro
cellular
model
vivo
acid
tnb
induc
coliti
mice
evalu
immunomodulatori
properti
f
prausnitzii
cell
transfect
report
gene
nfkb
activ
studi
show
follow
result
f
prausnitzii
effect
nfkb
activ
wherea
supernat
abolish
vitro
pbmc
stimul
f
prausnitzii
led
significantli
lower
ifngamma
product
level
higher
secret
oral
administr
either
live
f
prausnitzii
supernat
markedli
reduc
sever
tnb
coliti
tend
correct
dysbiosi
associ
tnb
coliti
demonstr
realtim
quantit
pcr
qpcr
analysi
conclus
result
show
f
prausnitzii
antiinflammatori
bacteri
candid
bacterium
exhibit
antiinflammatori
effect
partli
due
secret
metabolit
block
nfkb
activ
secret
vivo
effect
associ
decreas
proinflammatori
colon
cytokin
synthesi
induct
antiinflammatori
cytokin
secret
counter
balanc
dysbiosi
use
commens
bacterium
f
prausnitzii
candid
probiot
agent
appear
promis
strategi
cd
treatment
clinic
studi
requir
establish
diagnost
tool
defin
best
popul
patient
probiot
speci
especi
whether
clinic
benefit
pronounc
patient
low
level
endogen
firmicut
vilela
et
al
evalu
influenc
saccharomyc
boulardii
intestin
permeabl
cd
author
random
thirtyfour
patient
accord
vienna
classif
treatment
either
placebo
saccharomyc
boulardii
first
group
consist
patient
receiv
placebo
everi
h
oral
capsul
contain
mg
cellulos
mg
sucros
mg
magnesium
stearat
second
group
consist
patient
receiv
boulardii
everi
h
oral
capsul
formul
contain
mg
lyophil
boulardii
cell
mg
sucros
mg
magnesium
stearat
floratil
third
group
consist
healthi
volunt
age
year
mean
age
year
agre
take
part
studi
within
ethic
norm
human
research
submit
intestin
permeabl
test
order
establish
control
valu
assign
kind
treatment
baselin
medic
mesalamin
azathioprin
prednison
metronidazol
andor
thalidomid
maintain
intestin
permeabl
lm
ratio
evalu
immedi
begin
treatment
end
first
third
treatment
month
author
obtain
follow
result
volunt
lm
ratio
ae
wherea
valu
ae
patient
cd
p
placebo
group
increas
lm
ratio
ae
p
end
third
month
boulardii
group
improv
intestin
permeabl
decreas
lm
ratio
ae
p
period
previous
describ
result
bring
author
conclus
patient
cd
remiss
present
alter
integr
intestin
mucos
barrier
accord
lm
ratio
boulardii
ad
baselin
therapi
improv
intestin
permeabl
complet
normal
achiev
fujimori
et
al
realiz
studi
assess
clinic
use
combin
probiot
prebiot
therapi
treatment
activ
cd
ten
activ
cd
outpati
without
histori
oper
cd
enrol
cd
diagnos
establish
clinic
endoscop
radiolog
histolog
criteria
mean
ae
age
ae
year
main
symptom
present
diarrhea
abdomin
pain
patient
initi
therapeut
regimen
aminosalicyl
prednisolon
fail
achiev
remiss
patient
thu
initi
synbiot
therapi
consist
probiot
billion
cfu
daili
prebiot
psyllium
g
daili
probiot
mainli
compris
bifidobacterium
lactobacillu
patient
free
adjust
intak
probiot
prebiot
throughout
trial
chron
diseas
activ
index
cdai
intern
organ
studi
inflammatori
bowel
diseas
ioibd
score
blood
sampl
variabl
evalu
compar
trial
durat
trial
ae
month
end
therapi
patient
taken
ae
billion
cfu
daili
probiot
dose
six
patient
take
addit
ae
g
daili
psyllium
dose
seven
patient
improv
clinic
symptom
follow
combin
probiot
prebiot
therapi
cdai
ioibd
score
significantli
reduc
therapi
p
p
respect
six
patient
complet
respons
one
partial
respons
three
non
respond
two
patient
abl
discontinu
prednisolon
therapi
four
patient
decreas
intak
advers
event
highdos
probiot
prebiot
cotherapi
safe
effect
use
treatment
activ
cd
conclus
studi
show
synbiot
therapi
safe
reduc
cd
activ
achiev
remiss
found
synbiot
therapi
especi
indic
cd
patient
frequent
diarrhea
studi
examin
area
fecal
flora
scfa
compar
cd
patient
probiot
cd
patient
synbiot
expect
larger
scale
studi
random
control
studi
treatment
cd
probiot
therapi
combin
prebiot
clearli
necessari
fuller
appreci
therapeut
valu
synbiot
chermesh
et
al
design
prospect
multicent
random
studi
patient
random
activ
treatment
placebo
ratio
activ
treatment
consist
synbiot
contain
mixtur
prebiot
probiot
includ
lactic
acid
bacteria
ferment
fiber
four
lactic
acid
bacteria
pediacoccu
pentoseceu
l
raffinolacti
l
paracasei
susp
paracasei
l
plantarum
ferment
fiber
g
bglucan
g
inulin
g
pectin
g
resist
starch
author
check
treatment
synbiot
could
prevent
postop
recurr
patient
cd
followup
consist
endoscop
clinic
laboratori
paramet
thirti
patient
enrol
differ
found
treatment
group
regard
gender
age
diagnosi
age
surgeri
weight
smoke
statu
type
diseas
length
resect
segment
medic
treatment
prior
surgeri
differ
either
endoscop
clinic
relaps
rate
found
patient
treat
daili
dose
synbiot
placebo
small
studi
synbiot
effect
postop
recurr
patient
cd
larger
studi
patient
inflammatori
type
cd
undergo
surgeri
use
higher
dose
probiot
cocktail
may
prove
effect
studi
highlight
synbiot
effect
postop
recurr
patient
cd
van
gossum
et
al
design
multicent
clinic
trial
evalu
efficaci
oral
administr
probiot
l
johnsonii
nestec
earli
postop
endoscop
recurr
cd
seventi
patient
cd
enrol
prior
elect
ileocaec
resect
randomli
assign
surgeri
daili
treatment
either
lactobacillu
johnsonii
cfu
group
n
placebo
group
b
n
week
treatment
consist
probiot
freezedri
form
blend
maltodextrin
cfuday
placebo
maltodextrin
powder
suppli
foil
sachet
weight
g
contain
cfu
probiot
placebo
powder
appear
weight
also
individu
foil
packet
probiot
placebo
administ
combin
enter
formula
mlday
nunspeet
holland
konolfingen
switzerland
ident
treatment
sachet
blind
patient
support
staff
investig
numer
code
treatment
code
broken
statistician
complet
trial
primari
object
assess
effect
endoscop
recurr
rate
week
stratif
perform
accord
smoke
statu
random
seven
patient
exclud
placebo
group
respect
intentiontotreat
analysi
mean
endoscop
score
significantli
differ
two
treatment
group
month
versu
placebo
ae
versu
ae
treatment
effect
p
smoke
effect
p
percentag
patient
sever
recurr
placebo
group
respect
p
use
perprotocol
pp
analysi
mean
endoscop
score
significantli
differ
two
treatment
group
versu
placebo
group
ae
versu
ae
p
percentag
patient
sever
recurr
ae
placebo
group
respect
p
clinic
relaps
rate
clinic
relaps
rate
increas
clinic
relaps
rate
point
greater
baselin
placebo
group
respect
pp
analysi
chisquar
test
p
logrank
test
p
oral
administr
probiot
patient
cd
fail
prevent
earli
endoscop
recurr
week
ileocaec
resect
vasquez
et
al
analyz
compar
mucosaassoci
bacteria
mab
noninflam
inflam
ileal
mucosa
cd
patient
n
tissu
sampl
inflam
ileal
mucosa
adjac
noninflam
ileal
mucosa
taken
surgic
resect
specimen
mab
investig
use
fluoresc
situ
hybrid
groupspecif
probe
tempor
temperatur
gradient
gel
electrophoresi
ttge
sampl
noninflam
inflam
mucosa
taken
patient
biopsi
distribut
bacteri
popul
differ
noninflam
inflam
mucosa
bacteroidet
phylum
domin
account
mab
noninflam
tissu
inflam
area
proteobacteria
repres
mab
noninflam
inflam
area
clostridium
coccoid
group
firmicut
phylum
repres
mab
noninflam
tissu
versu
inflam
area
patient
similar
index
ttge
pair
profil
high
author
conclud
domin
mab
differ
noninflam
inflam
ileal
mucosa
cd
fact
argu
local
dysbiosi
explain
patchi
distribut
mucos
lesion
helicobact
pylori
h
pylori
small
curv
spiral
rodshap
bacterium
found
epitheli
mucu
surfac
patient
activ
gastriti
h
pylori
strongli
associ
duoden
peptic
ulcer
main
etiolog
agent
chronic
gastriti
gastric
cancer
gastric
malign
today
therapi
erad
bacterium
base
combin
antibiot
proton
pump
inhibitor
ppi
curea
breath
test
commonli
use
test
diagnos
presenc
h
pylori
stomach
test
also
find
applic
understand
h
pylori
erad
treatment
antibiot
urea
breath
test
base
abil
h
pylori
break
urea
chemic
made
nitrogen
carbon
carbon
dioxid
absorb
stomach
elimin
breath
test
patient
swallow
capsul
contain
urea
made
isotop
carbon
h
pylori
present
stomach
urea
broken
turn
carbon
dioxid
carbon
dioxid
absorb
across
line
stomach
blood
travel
blood
lung
excret
breath
sampl
exhal
breath
collect
isotop
carbon
exhal
carbon
dioxid
measur
isotop
detect
breath
mean
h
pylori
present
stomach
isotop
found
h
pylori
present
probiot
seem
direct
antimicrobi
effect
shown
vitro
studi
competit
h
pylori
inhibit
adher
product
metabolit
antimicrobi
molecul
implement
probiot
standard
antih
pylori
regimen
also
improv
patient
complianc
therapi
reduc
incid
side
effect
associ
antibiot
treatment
kim
et
al
perform
studi
evalu
whether
addit
probiot
ppibas
tripl
therapi
increas
success
erad
h
pylori
three
hundr
fortyseven
h
pylori
infect
patient
random
tripleplusyogurt
group
yogurt
group
n
tripleonli
group
control
group
n
tripl
therapi
consist
ppi
bid
clarithromycin
mg
bid
amoxicillin
g
bid
day
yogurt
group
receiv
tripl
therapi
week
one
bottl
yogurt
per
day
week
start
first
day
tripl
therapi
yogurt
korean
brand
contain
l
acidophilu
l
casei
b
longum
streptococcu
curea
breath
test
perform
least
week
complet
tripl
therapi
erad
rate
complianc
advers
event
compar
intent
treat
analysi
h
pylori
erad
rate
yogurt
group
similar
control
group
p
howev
mean
pp
analysi
erad
rate
yogurt
group
higher
control
group
p
common
advers
event
metal
tast
diarrhea
frequenc
advers
effect
yogurt
group
higher
control
group
p
howev
advers
event
mild
moder
intens
sever
advers
effect
similar
group
p
author
conclud
addit
yogurt
tripl
therapi
decreas
advers
effect
tripl
therapi
howev
increas
h
pylori
erad
rate
pp
analysi
suggest
possibl
addit
yogurt
commerci
kind
food
tripl
therapi
might
option
increas
h
pylori
erad
rate
imas
et
al
examin
intestin
microbiota
chang
h
pylori
erad
therapi
prevent
effect
probiot
agent
nineteen
patient
gastroduoden
ulcer
randomli
divid
three
group
group
without
probiot
group
b
regular
dose
group
c
doubl
dose
probiot
agent
contain
approxim
cfu
per
tablet
incid
diarrhea
soft
stool
h
pylori
erad
therapi
group
group
b
none
patient
group
c
report
diarrhea
soft
stool
bacteri
count
detect
rate
bifidobacteria
andor
oblig
anaerob
decreas
erad
therapi
howev
bacteri
count
oblig
anaerob
group
c
significantli
higher
group
p
addit
erad
therapi
c
difficil
toxin
detect
group
group
b
group
c
author
conclud
side
effect
associ
h
pylori
erad
therapi
includ
diarrhea
andor
soft
stool
consid
attribut
disturb
composit
intestin
microbiota
caus
antibiot
toxin
produc
c
difficil
result
studi
also
suggest
symptom
prevent
concomit
administr
viabl
bacteri
prepar
contain
francavilla
et
al
test
whether
lactobacillu
reuteri
atcc
reduc
h
pylori
intragastr
load
vivo
decreas
dyspept
reuteri
symptom
affect
erad
rate
convent
treatment
doubleblind
placebocontrol
studi
h
pylori
posit
subject
given
l
reuteri
placebo
day
week
l
reuteri
placebo
provid
biogaia
ab
sweden
chewabl
tablet
includ
either
l
reuteri
tablet
contain
cfu
l
reuteri
atcc
placebo
consist
tablet
ident
tast
appear
activ
studi
product
except
absenc
freezedri
l
reuteri
cryoprotect
everyon
underw
upper
endoscopi
curea
breath
test
h
pylori
stool
antigen
determin
entri
curea
breath
test
h
pylori
stool
antigen
use
qualit
semiquantit
marker
week
treatment
sequenti
treatment
administ
subsequ
everyon
vivo
l
reuteri
reduc
h
pylori
load
semiquantit
assess
curea
breath
test
deltavalu
h
pylori
stool
antigen
quantif
week
treatment
p
chang
shown
patient
receiv
placebo
l
reuteri
administr
follow
signific
decreas
gastrointestin
symptom
rate
scale
compar
pretreat
valu
p
present
one
receiv
placebo
p
signific
differ
erad
rate
observ
l
reuteri
effect
suppress
h
pylori
infect
human
decreas
occurr
dyspept
symptom
nevertheless
seem
affect
antibiot
therapi
outcom
author
report
supplement
l
reuteri
effect
reduc
h
pylori
bacteri
load
human
theoret
may
help
control
gastric
inflamm
cindoruk
et
al
investig
efficaci
safeti
boulardii
prevent
sideeffect
relat
h
pylori
erad
secondari
aim
studi
defin
effect
boulardii
erad
success
antih
pylori
therapi
one
hundr
twentyfour
patient
h
pylori
infect
male
femal
mean
age
ae
year
receiv
day
tripl
therapi
clarithromycin
mg
bid
amoxicillin
mg
bid
lansoprazol
mg
bid
randomli
assign
boulardii
placebo
dyspept
symptom
record
use
modifi
glasgow
dyspepsia
questionnair
gdq
sideeffect
profil
toler
assess
use
symptombas
questionnair
h
pylori
statu
recheck
week
complet
erad
therapi
h
pylori
erad
rate
although
higher
treatment
group
statist
similar
treatment
control
group
versu
respect
p
nine
patient
treatment
group
patient
placebo
group
experienc
diarrhea
p
epigastr
discomfort
frequent
control
group
versu
respect
p
diffus
abdomin
pain
abdomin
ga
tast
disturb
urticaria
nausea
symptom
similar
group
gdq
score
treatment
significantli
better
treatment
group
mean
ae
sd
rang
ae
vs
ae
respect
p
author
conclud
boulardii
improv
antih
pylori
antibiotherapyassoci
diarrhea
epigastr
discomfort
treatment
toler
addit
saccharomyc
boulardii
supplement
decreas
posttreat
dyspepsia
symptom
independ
h
pylori
statu
addit
boulardii
affect
rate
h
pylori
erad
scaccianoc
et
al
enrol
consecut
dyspept
patient
h
pylori
infect
patient
receiv
one
follow
therapi
standard
tripl
therapi
b
standard
tripl
therapi
plu
l
reuteri
supplement
c
tripl
therapi
plu
probiot
mixtur
standard
tripl
therapi
plu
probiot
mixtur
h
pylori
erad
check
use
curea
breath
test
perform
week
treatment
author
observ
therapi
plu
probiot
mixtur
tend
achiev
higher
erad
rate
lowest
incid
side
effect
observ
follow
therapi
plu
l
reuteri
highest
one
therapi
plu
probiot
mixtur
author
underlin
signific
statist
differ
therapi
regimen
studi
show
day
tripl
therapi
without
probiot
supplement
fail
achiev
accept
h
pylori
erad
rate
colon
cancer
multifactori
complex
neoplasm
involv
genet
environment
factor
seem
strong
relationship
colon
cancer
diet
intestin
microflora
ruptur
intestin
microflora
equilibrium
due
bad
diet
seem
relat
increas
risk
develop
colon
cancer
liong
underlin
differ
properti
attribut
probiot
prebiot
past
year
anticarcinogen
antimutagen
properti
abil
modifi
differenti
process
tumor
cell
product
scfa
alter
tumor
gene
express
also
evid
despit
posit
find
research
also
report
insignific
colon
cancer
protect
effect
certain
bacteri
speci
colon
produc
harm
substanc
seem
correl
cancer
thought
probiot
may
modul
sever
major
intestin
function
potenti
associ
develop
colon
cancer
prevent
growth
deleteri
organ
produc
anticarcinogen
substanc
move
balanc
gut
bacteria
favour
one
benefici
organ
colon
cancer
correl
high
fat
diet
thought
due
colon
rais
level
bile
acid
help
digest
fat
salt
releas
small
intestin
also
reabsorb
may
pass
colon
break
product
bile
may
cytotox
effect
cell
line
colon
increas
cell
prolifer
possibl
cancer
probiot
modul
intestin
microflora
may
affect
activ
one
enzym
form
toxic
product
probiot
may
also
reduc
toxic
bile
salt
bind
grow
colon
probiot
seem
exert
differ
function
control
growth
potenti
harm
bacteria
bind
mutagen
prevent
harm
enzym
activ
gut
bglucoronidas
nitroreductas
interact
cell
colon
form
conjug
linol
acid
compound
antiinflammatori
properti
may
inhibit
develop
cancer
may
also
increas
level
butyr
acid
colon
import
energi
sourc
growth
regul
colon
cell
stimul
activ
benefici
enzym
inactiv
carcinogen
glutathion
transferas
immun
system
produc
product
benefici
effect
cell
colon
lactobacillu
bifidobacterium
produc
lactic
acid
similar
scfa
increas
gut
lumen
acid
moreov
takeda
et
al
suggest
daili
intak
lactobacillu
casei
strain
shirota
provid
posit
effect
activ
nk
cell
seem
exert
key
role
protect
human
organ
cancer
hatakka
et
al
examin
fecal
bglucosidas
bglucuronidas
ureas
activ
administr
l
rhamnosu
togeth
propionibacterium
freudenreichii
ssp
shermanii
js
pj
thirtyeight
healthi
men
particip
random
doubleblind
placebocontrol
twoperiod
crossov
studi
treatment
period
week
subject
consum
daili
bacteri
placebo
capsul
bacteri
capsul
contain
viabl
pj
pj
commonli
use
manufactur
ripen
semihard
chees
freezedri
bacteria
fill
gelatin
capsul
subject
consum
daili
two
capsul
contain
viabl
pj
cfu
strain
daili
two
placebo
capsul
amount
particular
bacteri
combin
previous
shown
physiolog
effect
two
human
studi
amount
bacteria
capsul
remain
unchang
studi
addit
bacteria
capsul
contain
microcrystallin
cellulos
filler
placebo
capsul
ident
composit
without
bacteria
subject
instruct
take
capsul
daili
first
meal
day
activ
bglucosidas
bglucuronidas
ureas
recoveri
pj
count
total
lactobacilli
propionibacteria
determin
fece
mean
fecal
count
total
lactobacilli
propionibacteria
well
pj
strain
significantli
increas
administr
bacteria
respect
bglucosidas
activ
decreas
p
ureas
activ
p
bacteri
supplement
versu
placebo
chang
bglucosidas
activ
neg
correl
chang
propionibacteria
count
r
p
versu
nmolminmg
protein
subject
increas
unchangeddecreas
propionibacteria
respect
p
conclus
administr
pj
follow
increas
fecal
count
lactobacilli
propionibacteria
decreas
activ
bglucosidas
increas
count
propionibacteria
author
conclud
administr
togeth
pj
associ
decreas
bglucosidas
activ
relat
increas
count
propionibacteria
although
found
signific
influenc
activ
three
bacteri
enzym
bglucosidas
ureas
bglucuronidas
compar
placebo
evalu
effect
carcinogen
potenti
enzym
safeti
strain
studi
warrant
roller
et
al
investig
whether
daili
intak
syn
modul
immun
function
random
doubleblind
placebocontrol
trial
thirtyfour
colon
cancer
patient
undergon
cur
resect
forti
polypectom
patient
particip
subject
syn
group
daili
receiv
encapsul
bacteria
cfu
l
rhamnosu
gg
cfu
bifidobacterium
lacti
g
inulin
enrich
oligofructos
control
receiv
encapsul
maltodextrin
g
maltodextrin
prior
intervent
week
start
intervent
phagocyt
respiratori
burst
activ
neutrophil
monocyt
lytic
activ
nk
cell
product
well
tnfalpha
ifngamma
activ
pbmc
measur
fece
concentr
transform
growth
prostaglandin
measur
secret
activ
pbmc
polypectom
group
increas
significantli
p
cancer
group
syn
treatment
result
increas
capac
pbmc
produc
ifngamma
p
immunityrel
paramet
affect
syn
treatment
neither
cancer
polypectom
group
conclus
supplement
syn
minor
stimulatori
effect
system
immun
system
two
studi
group
author
conclud
thatno
neg
effect
observ
cancer
polypectom
patient
daili
consumpt
syn
week
definit
test
requir
indic
conclus
product
safe
syn
supplement
minor
effect
immun
system
subject
group
possibl
syn
supplement
human
preferenti
affect
gutassoci
lymphoid
tissu
rather
system
immun
system
rafter
et
al
verifi
whether
prebiot
concept
select
interact
colon
flora
nondigest
carbohydr
induc
synbiot
prepar
oligofructoseenrich
contain
inulin
orafti
tienen
belgium
l
rhamnosu
gg
abl
reduc
risk
colon
cancer
human
week
random
doubleblind
placebocontrol
trial
synbiot
food
compos
prebiot
probiot
l
rhamnosu
gg
conduct
colon
cancer
patient
polypectom
patient
treatment
consist
synbiot
prepar
contain
prebiot
probiot
strain
lactobacillu
delbreuckii
subspeci
rhamnosu
strain
gg
oligofructoseenrich
inulin
prepar
fecal
blood
sampl
obtain
intervent
colorect
biopsi
sampl
obtain
intervent
effect
synbiot
consumpt
batteri
intermedi
biomark
colon
cancer
examin
synbiot
intervent
result
signific
chang
fecal
flora
bifidobacterium
lactobacillu
increas
clostridium
perfringen
decreas
intervent
significantli
reduc
colorect
prolifer
capac
fecal
water
induc
necrosi
colon
cell
improv
epitheli
barrier
function
polypectom
patient
genotox
assay
colon
biopsi
sampl
indic
decreas
exposur
genotoxin
polypectom
patient
end
intervent
period
synbiot
consumpt
prevent
increas
secret
mean
pbmc
polypectom
patient
increas
product
interferon
cancer
patient
author
conclud
synbiot
intervent
result
signific
alter
composit
colon
bacteri
ecosystem
presum
consequ
metabol
activ
colon
result
also
provid
indirect
evid
consequ
synbiot
intervent
might
decreas
exposur
epithelium
cytotox
genotox
agent
decreas
colon
cell
prolifer
improv
mucosa
structur
diarrhea
increas
water
content
frequenc
volum
bowel
movement
probiot
could
import
treatment
diarrhea
ill
viral
diarrhea
antibioticassoci
diarrhea
clostridium
difficilerel
diarrhea
travel
diarrhea
td
viral
gastroenter
character
wateri
diarrhea
vomit
headach
fever
chill
abdomin
pain
virus
may
respons
condit
ratavirus
calicivirus
adenovirus
astrovirus
torovirus
coronavirus
pestivirus
citomegalovirus
respons
viral
coliti
rotaviru
common
caus
viral
diarrhea
injur
intestin
epithelium
lead
malabsorpt
increas
secret
epithelium
rotaviru
sever
way
transmiss
fecalor
contamin
water
suplli
poor
hygien
food
fomit
saavedra
et
al
report
lactobacillu
gg
observ
decreas
rate
rotavirusassoci
diarrhea
rotavir
shred
moreov
author
report
interest
studi
highlight
children
treat
lactobacillu
gg
iga
specif
antibodysecret
cell
sasc
respons
rotaviru
versu
placebo
anoth
studi
perform
infant
describ
infecti
diarrhea
success
treat
ad
combin
bifidobacteria
streptococcu
thermophilu
powder
formula
studi
show
combin
b
bifidum
thermophilu
also
reduc
rate
rotavirusassoci
diarrhea
decreas
rotaviru
shred
td
condit
usual
due
ingest
food
beverag
contamin
fecal
matter
case
bacteria
caus
common
bacteria
enterotoxigen
e
coli
enteroaggreg
e
coli
campylobact
jejuni
salmonella
speci
aeromona
speci
protozoa
entamoeba
histolytica
giardia
lamblia
enterovirus
gener
minor
caus
td
episod
diarrhea
frequent
side
effect
antibiot
therapi
antibiot
therapi
lead
alter
normal
intestin
flora
may
caus
loss
colon
resist
alter
metabol
function
normal
flora
first
situat
follow
abnorm
growth
pathogen
organ
c
difficil
candida
albican
kcaytoca
salmonella
spp
respons
toxigen
diarrhea
second
situat
lead
diminish
digest
non
absorb
carbohydr
follow
osmot
water
secret
diminish
colic
absorpt
water
electrolyt
caus
diminish
product
scfa
result
diarrhea
dubey
et
al
conduct
doubleblind
random
placebocontrol
studi
evalu
efficaci
toler
vsl
sharp
cd
pharma
india
treatment
acut
rotaviru
diarrhea
children
patient
randomli
assign
receiv
day
oral
treatment
vsl
sharp
probiot
mixtur
placebo
addit
usual
care
diarrhea
use
probiot
mixtur
vsl
sharp
acut
rotaviru
diarrhea
result
earlier
recoveri
reduc
frequenc
oral
rehydr
salt
or
administr
reflect
decreas
stool
volum
loss
diarrhea
without
side
effect
narayanappa
et
al
evalu
efficaci
safeti
bifilac
reduc
episod
frequenc
durat
diarrhea
induc
rotavir
infect
evalu
efficaci
bifilac
amelior
associ
symptom
like
dehydr
durat
rotavir
shed
fece
author
enrol
children
age
month
year
divid
group
one
group
receiv
standard
therapi
placebo
group
receiv
standard
therapi
probiot
bifilac
randomli
children
assess
frequenc
durat
diarrhea
degre
dehydr
durat
volum
or
therapi
durat
volum
intra
venou
fluid
durat
rotavir
shed
conclud
synbiot
bifilac
appear
safe
effect
adjuv
manag
acut
rotavir
diarrhea
henker
et
al
determin
whether
stool
frequenc
infant
toddler
suffer
acut
diarrhea
could
normal
quickli
administ
probiot
escherichia
coli
nissl
ecn
solut
rather
administ
placebo
author
also
assess
safeti
ecn
total
children
age
month
acut
diarrhea
three
wateri
loos
stool
h
random
either
group
receiv
probiot
ecn
suspens
n
group
receiv
placebo
suspens
n
confirm
doubleblind
clinic
trial
depend
age
patient
ml
per
day
verum
suspens
viabl
ecn
cell
per
millilitr
placebo
administ
oral
caus
diarrhea
viral
rather
bacteri
ecn
found
safe
welltoler
show
signific
superior
compar
placebo
treatment
acut
diarrhea
infant
toddler
basu
et
al
evalu
role
l
rhamnosu
gg
probiot
acut
wateri
diarrhea
awd
random
control
blind
trial
involv
patient
intervent
group
n
receiv
or
probiot
powder
contain
million
cell
l
rhamnosu
gg
control
group
n
receiv
or
alon
twice
daili
minimum
period
day
till
diarrhea
ceas
studi
period
patient
receiv
or
andor
iv
fluid
ongo
loss
nutrit
supplement
none
receiv
antibiot
antidiarrho
medic
rotaviru
isol
signific
differ
treatment
group
daili
frequenc
durat
diarrhea
vomit
length
hospit
stay
complic
observ
use
l
rhamnosu
gg
l
rhamnosu
gg
supplement
decreas
frequenc
durat
diarrhea
vomit
children
awd
reduc
hospit
stay
patient
efficaci
combin
b
longum
l
rhamnosu
l
plantarum
prevent
antibioticassoci
diarrhea
children
evalu
szymanski
et
al
seventyeight
children
age
month
year
otiti
media
andor
respiratori
tract
infect
andor
uti
enrol
doubleblind
random
control
trial
receiv
standard
antibiot
treatment
plu
food
supplement
contain
cfu
b
longum
l
rhamnosu
l
plantarum
n
placebo
n
oral
twice
daili
durat
antibiot
treatment
patient
receiv
probiot
similar
rate
diarrhea
loos
wateri
stoolsday
h
occur
week
antibiot
therapi
receiv
placebo
rel
risk
ci
mean
number
stool
per
day
significantli
lower
experiment
group
mean
differ
stoolday
ci
advers
event
report
conclud
three
probiot
significantli
alter
rate
diarrhea
although
reduc
frequenc
stool
per
day
author
underlin
overal
frequenc
diarrhea
surprisingli
low
even
though
result
interpret
caution
ruszczynski
et
al
enrol
children
common
infect
age
month
year
doubleblind
random
placebocontrol
trial
assess
efficaci
administr
l
rhamnosu
prevent
antibioticassoci
diarrhea
children
receiv
standard
antibiot
treatment
plu
cfu
probiot
l
rhamnosu
strain
en
oxi
pen
n
placebo
n
administ
oral
twice
daili
throughout
antibiot
treatment
diarrhea
loos
wateri
stool
day
h
occur
week
antibiot
therapi
occur
nine
patient
probiot
group
patient
placebo
group
rel
risk
rr
ci
three
children
probiot
group
develop
diarrhea
caus
clostridium
difficil
otherwis
unexplain
diarrhea
compar
nine
placebo
group
rr
ci
advers
event
observ
studi
show
administr
l
rhamnosu
strain
en
oxi
pen
children
receiv
antibiot
reduc
risk
diarrhea
beausoleil
et
al
design
studi
assess
efficaci
safeti
ferment
milk
combin
l
acidophilu
l
casei
wide
avail
canada
prevent
antibioticassoci
diarrhea
aad
doubleblind
random
studi
ivolv
hospit
patient
randomli
assign
receiv
either
lactobacillifer
milk
placebo
daili
basi
aad
occur
seven
patient
lactobacilli
group
patient
placebo
group
ci
p
median
hospit
durat
eight
day
lactobacilli
group
compar
day
placebo
group
p
studi
show
daili
administr
lactobacillifer
milk
safe
effect
prevent
antibioticassoci
diarrhea
hospit
patient
hickson
et
al
design
studi
involv
hospit
patient
mean
age
take
antibiot
random
doubleblind
placebocontrol
studi
aim
determin
efficaci
probiot
drink
contain
lactobacillu
prevent
diarrhea
associ
antibiot
use
caus
clostridium
difficil
patient
receiv
g
ml
drink
contain
l
casei
l
bulgaricu
thermophilu
twice
day
cours
antibiot
one
week
cours
finish
placebo
group
receiv
longlif
steril
milkshak
probiot
group
develop
diarrhea
associ
antibiot
use
compar
placebo
group
p
logist
regress
control
factor
gave
use
probiot
low
albumin
sodium
also
increas
risk
diarrhea
absolut
risk
reduct
number
need
treat
one
probiot
group
placebo
group
diarrhea
caus
c
difficil
p
absolut
risk
reduct
number
need
treat
conclud
consumpt
probiot
drink
contain
l
casei
l
bulgaricu
thermophilu
reduc
incid
aad
c
difficil
associ
diarrhea
wenu
et
al
studi
prevent
effect
milk
drink
ferment
multistrain
probiot
aad
design
doubleblind
placebocontrol
studi
involv
patient
random
ingest
ferment
milk
drink
contain
l
rhamnosu
gg
n
placebo
heatkil
bacteria
n
period
day
sixtythre
patient
complet
studi
accord
protocol
two
patient
treatment
group
eight
placebo
group
develop
aad
p
rel
risk
develop
aad
ci
given
probiot
milk
drink
studi
prove
ferment
multistrain
probiot
milk
drink
may
prevent
four
five
case
aad
adult
hospit
patient
kone
et
al
studi
effect
multispeci
probiot
composit
metabol
activ
intestin
microbiota
bowel
habit
fortyon
healthi
volunt
given
mg
amoxycillin
twice
daili
day
random
either
g
multispeci
probiot
ecolog
aad
cfug
placebo
twice
daili
day
collect
fece
analyz
composit
intestin
microbiota
betaeglucosidas
activ
endotoxin
concentr
c
difficil
toxin
scfa
ph
determin
bowel
movement
score
accord
bristol
stool
form
scale
mean
number
enterococci
increas
significantli
log
day
log
day
log
day
cfug
fece
p
probiot
intak
although
signific
differ
observ
intervent
group
within
group
signific
chang
found
time
microbi
composit
metabol
activ
moreov
bowel
movement
frequenc
per
day
least
day
andor
consist
least
day
report
less
frequent
probiot
compar
placebo
group
vs
p
studi
show
apart
increas
enterococci
signific
differ
microbi
composit
metabol
activ
observ
probiot
compar
placebo
group
howev
chang
time
present
group
differ
significantli
probiot
placebo
arm
suggest
amoxycillin
effect
modul
probiot
intak
intak
multispeci
probiot
significantli
reduc
diarrhealik
bowel
movement
healthi
volunt
receiv
amoxicillin
sabia
et
al
focus
plasmid
transfer
mate
process
occur
gut
microbiota
process
particularli
import
antibioticresist
gene
involv
author
investig
vitro
capabl
two
l
plantarum
strain
one
bacteriocin
produc
one
non
produc
interfer
conjug
process
differ
mate
perform
ad
donor
recipi
cell
l
plantarum
bac
l
plantarum
bac
agent
interfer
conjug
ad
staphylococcu
aureu
strain
without
agent
interfer
use
control
lactobacillu
strain
abl
decreas
mate
frequenc
statist
signific
differ
viabl
transconjug
obtain
presenc
absenc
lactobacilli
effect
almost
two
l
plantarum
independ
bacteriocin
product
trial
perform
streptococcu
aureu
decreas
mate
frequenc
observ
confirm
capabl
interfer
rplasmid
transfer
abil
properti
test
l
plantarum
strain
hoesl
et
al
focus
interest
studi
involv
admnistr
oxalobact
formigen
discov
bacterium
respons
degrad
oxal
human
bodi
sever
studi
show
link
lack
colon
formigen
recurr
oxal
stone
format
moreov
among
stone
former
lack
formigen
associ
hyperoxaluria
higher
urinari
oxal
excret
femal
calcium
oxal
former
recurr
uti
may
associ
applic
antibiot
subsequ
erad
formigen
perman
decolon
also
found
cystic
fibrosi
patient
author
analyz
clinic
trial
involv
human
follow
administr
mg
formigen
strain
hcl
urinari
oxal
excret
oxalatecreatinin
ratio
found
reduc
formigen
use
first
time
cinic
trial
involv
children
seven
still
function
kidney
two
endstag
kidney
failur
affect
primari
hyperoxaluria
type
inherit
life
threaten
diseas
character
recurr
oxal
stone
format
nephrocalcinosi
eventu
liver
kidney
failur
administ
daili
teaspoon
frozen
cell
past
live
formigen
oxal
excret
urin
children
function
kidney
decreas
percent
percent
follow
gradual
increas
treatment
stop
two
children
renal
dialysi
signific
reduct
blood
level
oxal
observ
hopp
et
al
design
new
studi
oral
administ
oxalobact
week
frozen
past
entericco
capsul
nine
patient
five
normal
renal
function
one
liverkidney
transplant
three
renal
failur
complet
studi
seven
patient
six
normal
renal
function
one
liverkidney
transplant
complet
studi
preliminari
obtain
data
indic
oxalobact
formigen
safe
lead
signific
reduct
either
urinari
plasma
oxal
potenti
new
treatment
option
primari
hyperoxaluria
skovbjerg
et
al
design
doubleblind
pilotpreliminari
studi
involv
children
longstand
secretori
otiti
media
som
patholog
character
persist
fluid
middl
ear
caviti
schedul
insert
tympanostomi
tube
random
nasal
spray
treatment
streptococcu
sanguini
l
rhamnosu
placebo
day
surgeri
clinic
evalu
carri
day
treatment
middl
ear
fluid
mef
collect
surgeri
quantif
cytokin
detect
bacteria
cultur
pcr
nasopharyng
swab
obtain
treatment
surgeri
author
observ
complet
signific
clinic
recoveri
occur
patient
treat
sanguini
compar
patient
placebo
group
p
l
rhamnosu
treatment
group
patient
cure
much
better
p
compar
placebo
spray
treatment
alter
composit
nasopharyng
flora
cytokin
pattern
observ
nasopharynx
mef
except
higher
level
found
nasopharynx
l
rhamnosu
treat
children
although
mechan
effect
remain
investig
studi
show
spray
treatment
sanguini
may
effect
som
probiot
seem
play
import
role
lumen
gut
elabor
antibacteri
molecul
bacteriocin
moreov
seem
abl
enhanc
mucos
barrier
increas
product
innat
immun
molecul
includ
goblet
cellederiv
mucin
trefoil
factor
defensin
produc
intestin
paneth
cell
strain
promot
adapt
immun
respons
secretori
immun
globulin
regulatori
cell
probiot
capac
activ
receptor
enter
nervou
system
could
use
promot
pain
relief
set
viscer
hyperalgesia
moreov
probiot
exert
import
action
improv
abnorm
colon
flora
intestin
microflora
could
effect
treat
variou
patholog
prevent
dysbiosi
character
associ
condit
futur
clinic
trial
involv
larg
number
patient
mandatori
achiev
definit
evid
prevent
cur
role
probiot
medic
practic
detail
correct
formul
term
amount
bacteria
viabil
associ
growth
factor
requir
order
standard
administr
schedul
achiev
homogen
compar
result
select
cohort
recruit
patient
